mhtx_10q.htm

0001477932-19-006712.txt : 20191119 0001477932-19-006712.hdr.sgml : 20191119 20191119161108 ACCESSION NUMBER: 0001477932-19-006712 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 38 CONFORMED PERIOD OF REPORT: 20190930 FILED AS OF DATE: 20191119 DATE AS OF CHANGE: 20191119 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MANHATTAN SCIENTIFICS INC CENTRAL INDEX KEY: 0001099132 STANDARD INDUSTRIAL CLASSIFICATION: MISCELLANEOUS ELECTRICAL MACHINERY, EQUIPMENT & SUPPLIES [3690] IRS NUMBER: 850460639 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-28411 FILM NUMBER: 191231276 BUSINESS ADDRESS: STREET 1: 244 FIFTH AVENUE STREET 2: SUITE 2341 CITY: NEW YORK STATE: NY ZIP: 10001 BUSINESS PHONE: 212-541-2405 MAIL ADDRESS: STREET 1: 244 FIFTH AVENUE STREET 2: SUITE 2341 CITY: NEW YORK STATE: NY ZIP: 10001 10-Q 1 mhtx_10q.htm FORM 10-Q mhtx_10q.htm

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

FORM 10-Q

(Mark One)

x	QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934

For the fiscal quarter ended September 30, 2019

¨	TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT

For the transition period from ____________to____________

Commission file number 000-28411

MANHATTAN SCIENTIFICS, INC.

(Exact name of small business issuer as specified in its charter)

Delaware

000-28411

85-0460639

(State of

Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

244 Fifth Ave, Suite 2341

New York, New York, 10001

(Address of principal executive offices) (Zip code)

Issuer’s telephone number: (212) 541-2405

Securities registered under Section 12(b) of the Exchange Act: None

Securities registered under Section 12(g) of the Exchange Act:

Common Stock, $0.001 par value

(Title of Class)

Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	¨	Accelerated filer	¨
Non-accelerated filer	¨	Smaller reporting company	x
		Emerging growth company	¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

There were 557,781,064 shares outstanding of registrant’s common stock, par value $0.001 per share, as of November 19, 2019.

TABLE OF CONTENTS

PART I

Item 1.	Condensed Financial Statements	3
	Condensed Consolidated Balance Sheets as of September 30, 2019 (unaudited) and December 31, 2018		3
	Unaudited Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2019 and 2018		4
	Unaudited Condensed Consolidation Statements of Stockholders’ Equity for the three and nine months ended September 30, 2019		5
	Unaudited Condensed Consolidation Statements of Stockholder’s Equity for the three and nine months ended September 30, 2018		6
	Unaudited Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2019 and 2018		7
	Condensed Notes to Consolidated Financial Statements (Unaudited)		8
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operation		14
Item 3.	Quantitative and Qualitative Disclosures About Market Risk		18
Item 4.	Controls and Procedures		18

PART II

Item 1.	Legal Proceedings		19
Item 1A.	Risk Factors		19
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds		22
Item 3.	Defaults Upon Senior Securities		22
Item 4.	Mine Safety Disclosure		22
Item 5.	Other Information		22
Item 6.	Exhibits		23
SIGNATURES			24

Table of Contents

PART I – FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(rounded)

September 30,

December 31,

2019

2018

(unaudited)

ASSETS

Current assets:

Cash

$ 144,000

$ 87,000

Prepaid expenses

6,000

11,000

Due from the sale of assets - current portion

300,000

-

Total current assets

450,000

98,000

Investment in equity securities

2,117,000

1,354,000

Property and equipment, net

6,000

6,000

Assets held for sale

-

1,200,000

Due from the sale of assets held for sale

600,000

-

Other assets

2,000

2,000

Total assets

$ 3,175,000

$ 2,660,000

LIABILITIES

Current liabilities:

Accounts payable and accrued expenses

$ 237,000

$ 221,000

Accrued expenses — related parties

1,778,000

1,531,000

Total current liabilities

2,015,000

1,752,000

Long-term liabilities:

Total long-term liabilities

-

-

Total liabilities

2,015,000

1,752,000

Commitments and Contingencies - Note 8

Series D convertible preferred mandatory redeemable, authorized 105,671 shares, 105,671 and 105,671 shares issued and outstanding, respectively

1,058,000

1,058,000

STOCKHOLDERS’ EQUITY (DEFICIT)

Capital stock $.001 par value

Preferred, authorized 447,804 shares, 0 and 0 shares issued, and outstanding, respectively

-

-

Class A Convertible Preferred, authorized 182,525, 0 and 0 shares issued and outstanding, respectively

-

-

Class B Convertible Preferred, authorized 250,000, 49,999 and 49,999 shares issued and outstanding, respectively

-

-

Class C Redeemable Convertible Preferred, authorized 14,000, 0 and 0 shares issued and outstanding, respectively

-

-

Common, authorized 950,000,000 shares, 557,781,064 and 533,781,064 shares issued, and outstanding, respectively

558,000

534,000

Additional paid-in-capital

67,632,000

67,289,000

Accumulated deficit

(68,088,000 )

(67,973,000 )
Total stockholders' equity (deficit)

102,000

(150,000 )
TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS’ EQUITY (DEFICIT)

$ 3,175,000

$ 2,660,000

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

3

Table of Contents

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited) (rounded)


	THREE MONTHS ENDED						NINE MONTHS ENDED
	September 30,						September 30,
	2019			2018			2019			2018

Revenue	$	22,000		$	-		$	72,000		$	-

Operating costs:
Direct cost of revenue		-			-			-			7,000
General and administrative expenses		187,000			322,000			945,000			1,089,000
Research and development		3,000			-			6,000			52,000
Asset impairment		-			-			-			842,000

Total operating costs and expenses		190,000			322,000			951,000			1,990,000

Loss from operations		(168,000	)		(322,000	)		(879,000	)		(1,990,000	)

Other income and (expenses):
Gain (loss) on fair value adjustment of investments		1,397,000			646,000			764,000			(2,727,000	)

Net loss before provision for income taxes
Income tax expense		-			-			-			-

NET INCOME (LOSS)	$	1,229,000		$	324,000		$	(115,000	)	$	(4,717,000	)

BASIC AND DILUTED INCOME (LOSS) PER COMMON SHARE:

Weighted average number of common shares outstanding (Basic)		557,781,064			533,781,064			546,528,317			533,781,064

Basic income (loss) per common share	$	0.00		$	0.00		$	(0.00	)	$	(0.01	)

Weighted average number of common shares outstanding (Diluted)		597,886,064			584,579,246			546,528,317			533,781,064

Diluted income (loss) per common share	$	0.00		$	0.00		$	(0.00	)	$	(0.01	)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

4

Table of Contents

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)
For the Nine Months Ended September 30, 2019
(unaudited) (rounded)


	Preferred Stock $0.001 Par Value				Common Stock				Additional
	Series B				$0.001 Par Value				Paid-In		Accumulated
	Shares		Amount		Shares		Amount		Capital		Deficit			Total


Balance December 31, 2018		49,999	$	-		533,781,064	$	534,000	$	67,289,000	$	(67,973,000	)	$	(150,000	)

Net loss												(436,000	)		(436,000	)

Balance March 31, 2019		49,999		-		533,781,064		534,000		67,289,000		(68,409,000	)		(586,000	)

Common stock issued for services		-		-		24,000,000		24,000		336,000		-			360,000

Options issued for services		-		-		-		-		7,000		-			7,000

Net loss												(908,000	)		(908,000	)

Balance June 30, 2019		49,999		-		557,781,064		558,000		67,632,000		(69,317,000	)		(1,127,000	)

Net income												1,229,000			1,229,000

Balance September 30, 2019		49,999	$	-		557,781,064	$	558,000	$	67,632,000	$	(68,088,000	)	$	102,000

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

5

Table of Contents

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)
For the Nine Months Ended September 30, 2018
(unaudited)
(rounded)

Preferred Stock $0.001 Par Value

Common Stock

Additional

Series B

$0.001 Par Value

Paid-In

Accumulated

Shares

Amount

Shares

Amount

Capital

Deficit

Total

Balance December 31, 2017

49,999

533,781,064

534,000

67,289,000

(59,662,000

)

8,161,000

Net loss

(2,828,000

)

(2,828,000

)

Balance March 31, 2018

49,999

533,781,064

534,000

67,289,000

(62,490,000

)

5,333,000

Net loss

(2,213,000

)

(2,213,000

)

Balance June 30, 2018

49,999

533,781,064

534,000

67,289,000

(64,703,000

)

3,120,000

Net income

324,000

Balance September 30, 2018

49,999

533,781,064

534,000

67,289,000

(64,379,000

)

3,444,000

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

6

Table of Contents

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

(rounded)

NINE MONTHS ENDED

September 30,

2019

2018

CASH FLOWS FROM OPERATING ACTIVITIES:

Net loss

$ (115,000 )

$ (4,717,000 )
Adjustments to reconcile net loss to net cash used in operating activities:

Common stock issued for services

360,000

-

Stock options issued/vested for services

7,000

-

Depreciation and amortization

1,000

496,000

Asset impairment

-

842,000

Gain (loss) on fair value adjustment of investments

(764,000 )

2,727,000

Changes in:

Prepaid expenses

5,000

7,000

Accounts payable and accrued expenses

263,000

118,000

Net cash used in operating activities

(243,000 )

(527,000 )

CASH FLOWS FROM INVESTING ACTIVITIES:

Purchase of fixed assets

(2,000 )

-

Proceeds from sale of assets held for sale

300,000

500,000

Proceeds from sale of investments

2,000

-

Net cash used in investing activities

300,000

500,000

CASH FLOWS FROM FINANCING ACTIVITIES:

Net cash provided by financing activities

-

-

NET DECREASE IN CASH

57,000

(27,000 )
CASH, BEGINNING OF PERIOD

87,000

269,000

CASH, END OF PERIOD

$ 144,000

$ 242,000

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:

Interest paid

$ -

$ -

Income taxes paid

$ -

$ -

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

7

Table of Contents

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

(UNAUDITED)

(ROUNDED)

NOTE 1 – BASIS OF PRESENTATION

The foregoing unaudited interim financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions for Form 10-Q and Regulation S-X as promulgated by the Securities and Exchange Commission (“SEC”). Accordingly, these financial statements do not include all of the disclosures required by generally accepted accounting principles in the United States of America for complete financial statements. These unaudited interim financial statements should be read in conjunction with the audited financial statements and the notes thereto included on Form 10-K for the year ended December 31, 2018, filed on March 29, 2019. In the opinion of management, the unaudited interim financial statements furnished herein include all adjustments, all of which are of a normal recurring nature, necessary for a fair statement of the results for the interim period presented.

The preparation of financial statements in accordance with generally accepted accounting principles in the United States of America requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published, and the reported amounts of revenues and expenses during the reporting period. Uncertainties with respect to such estimates and assumption are inherent in the preparation of the Company’s financial statements; accordingly, it is possible that the actual results could differ from these estimates and assumptions that could have a material effect on the reported amounts of the Company’s financial position and results of operations.

Operating results for the nine-month period ended September 30, 2019 are not necessarily indicative of the results that may be expected for the year ending December 31, 2019. The condensed consolidated balance sheet at December 31, 2018 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by generally accepted accounting principles in the U.S. for complete financial statements.

NOTE 2 – GOING CONCERN

As of September 30, 2019, the Company has cumulative losses totaling $68,088,000 and negative working capital of $1,565,000. The Company incurred a net loss of $115,000 for the nine months ended September 30, 2019. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. Because of these conditions, the Company will require additional working capital to develop business operations. Management’s plans are to raise additional working capital through the continued licensing of its technology as well as to generate revenues for other services. There are no assurances that the Company will be able to achieve the level of revenues adequate to generate sufficient cash flow from operations to support the Company’s working capital requirements. To the extent that funds generated are insufficient, the Company will have to raise additional working capital. No assurance can be given that additional financing will be available, or if available, will be on terms acceptable to the Company. If adequate working capital is not available, the Company may not continue its operations.

The financial statements do not include any adjustments relating to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS

BASIS OF CONSOLIDATION:

The consolidated financial statements include the accounts of Manhattan Scientific, Inc., its wholly owned subsidiary Metallicum. All significant intercompany balances and transactions have been eliminated.

USE OF ESTIMATES:

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amount of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. A significant estimate includes the carrying value of the Company’s patents, fair value of the Company’s common stock, assumptions used in calculating the value of stock options, depreciation and amortization.

8

Table of Contents

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

(UNAUDITED)

(ROUNDED)

CASH CONCENTRATION:

The Company’s cash accounts are federally insured up to $250,000 for each financial institution we hold our accounts in. As of September 30, 2019 and December 31, 2018, the cash balances did not exceed the federally insured limits.

INTANGIBLE ASSETS:

License Agreements

In 2008, the Company obtained licenses to the rights of certain patents regarding nanostructured materials developed by another company as a result of the acquisition of Metallicum. The purchase price paid for these licenses was $305,000, which represented its fair value. The Company obtained an exclusive license on two patents and a non-exclusive license on the third patent. The value attributable to license agreements is being amortized over the period of its estimated benefit period of 10 years. At September 30, 2019 and December 31, 2018, the license agreements were fully amortized. Under the terms of the agreement, the Company may be required to pay royalties, as defined, to the licensors.

In 2009, the Company entered into a patent license agreement with Los Alamos National Security LLC for the exclusive use of certain technology relating to the manufacture and application of nanostructuring metals and alloys. The purchase price paid for this license agreement was $33,000 based on the fair market value of 2,000,000 shares of common stock issued. The value attributable to license agreements is being amortized over the period of its estimated benefit period of 10 years. At September 30, 2019 and December 31, 2018, the license agreements were fully amortized. Beginning in 2010, the Company was required to pay an annual license fee of $10,000 and may be required to pay royalties, as defined, to the licensors.

ASSETS HELD FOR SALE:

Non-current assets are classified as held for sale if it is highly probably that they will be recovered primarily through sale rather than through continuing use.

Immediately before classification as held for sale, the assets are remeasured at the lower of their carrying amount and fair value less costs to sell. Any impairment loss on initial classification as held for sale and subsequent gains and losses on re-measurement are recognized in profit or loss. Gains are not recognized in excess of any cumulative impairment loss.

During the nine months ended September 30, 2019, the Company sold the assets held for sale that were presented on the balance sheet as of December 31, 2018. During the year ended December 31, 2018, the Company recorded impairment and adjusted the asset valuation to $1.2 million. The Company sold the assets for a total of $1.2 million of which $300,000 was received during the three-month period ended June 30, 2019. The remaining $900,000 will be collected during the next three years in equal increments on the anniversary date of the agreement.

REVENUE RECOGNITION:

The Company recognizes revenue in accordance with generally accepted accounting principles as outlined in the Financial Accounting Standard Board’s (“FASB”) Accounting Standards Codification (“ASC”) 606, Revenue From Contracts with Customers, which consists of five steps to evaluating contracts with customers for revenue recognition: (i) identify the contract with the customer; (ii) identity the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price; and (v) recognize revenue when or as the entity satisfied a performance obligation.

Revenue recognition occurs at the time we satisfy a performance obligation to our customers, when control transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. We only record revenue when collectability is probable.

9

Table of Contents

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

(UNAUDITED)

(ROUNDED)

FAIR VALUE OF FINANCIAL INSTRUMENTS

Effective January 1, 2008, the Company adopted FASB ASC 820, Fair Value Measurements and Disclosures, Pre Codification SFAS No. 157, “Fair Value Measurements”, which provides a framework for measuring fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The standard also expands disclosures about instruments measured at fair value and establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:

Level 1 — Quoted prices for identical assets and liabilities in active markets;

Level 2 — Quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets; and

Level 3 — Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

The Company designates cash equivalents (consisting of money market funds) and investments in securities of publicly traded companies as Level 1. The total amount of the Company’s investment classified as Level 3 is de minimis.

Fair value of financial instruments: The carrying amounts of financial instruments, including cash and cash equivalents, short-term investments, accounts payable, accrued expenses and notes payables approximated fair value as of September 30, 2019 and December 31, 2018 because of the relative short term nature of these instruments.

During the year ended December 31, 2017, the Company elected fair value option for its investment in Imagion Biosystems, Inc. a Nevada company (“Imagion”) based on triggering event of dilution of ownership, which lead to the deconsolidation of Imagion. Investments in Imagion are measured at fair value as opposed to equity method based on ASC 825-10. The guidance allows entities to elect to measure certain financial assets and financial liabilities (as well as certain nonfinancial instruments that are similar to financial instruments) at fair value. Investments over which an investor has the ability to exercise significant influence are eligible for the fair value option as they represent recognized financial assets. When the fair value option is elected for an instrument, all subsequent changes in fair value for that instrument are reported in earnings.

As of September 30, 2019, the Company holds approximately 19% of the total issued and outstanding shares of Imagion and is reported under fair value method under ASC 320. Management determined that it was appropriate to carry its investment in Imagion at fair value because the investment is traded on the Australian stock exchange and has daily trading activity and is a better indicator of value. The investments are re-measured at the end of each quarter based on the trading price and converted from AUD to USD. Any change in the value is reported on the income statement as an unrealized gain or loss.

Table of Contents

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

(UNAUDITED)

(ROUNDED)

INCOME TAXES

The Company accounts for income taxes under an asset and liability approach. This process involves calculating the temporary and permanent differences between the carrying amounts of the assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The temporary differences result in deferred tax assets and liabilities, which would be recorded on the Company’s consolidated balance sheets in accordance with ASC 740, which established financial accounting and reporting standards for the effect of income taxes. The Company must assess the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent the Company believes that recovery is not likely, the Company must establish a valuation allowance. Changes in the Company’s valuation allowance in a period are recorded through the income tax provision on the consolidated statements of operations.

ASC 740-10 clarifies the accounting for uncertainty in income taxes recognized in an entity’s financial statements and prescribes a recognition threshold and measurement attributes for financial statement disclosure of tax positions taken or expected to be taken on a tax return.

Under ASC 740-10, the impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Additionally, ASC 740-10 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. As a result of the implementation of ASC 740-10, the Company recognized no material adjustment in the liability for unrecognized income tax benefits.

BASIC AND DILUTED LOSS PER SHARE

In accordance with FASB ASC 260, “Earnings Per Share,” the basic loss per share is computed by dividing the loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Basic net loss per share excludes the dilutive effect of stock options or warrants and convertible notes. Diluted net earnings (loss) per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents, consisting of shares that might be issued upon exercise of common stock options and warrants. In periods where losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. As of September 30, 2019 and 2018, 40,105,000 and 50,798,182, respectively, dilutive shares were excluded from the calculation of diluted loss per common share for the nine months ended but were included for the diluted earnings per share calculation for the three months ended.

LEASES

The Company leases a facility with terms of month to month for its headquarters and had a lease on a facility through April 2021. The lease may be cancelled at any time with three months written notice before April 2020 and 2021, the anniversary dates of the lease. The Company adopted ASC 842 on January 1, 2019 and has evaluated and has no impact on the financial statements as under the practical expedient the leases consist of terms less then one year, and therefore is not required to capitalize the lease.

During June 2019, the Company entered into an assignment and assumption of lease with the landlord and another entity for the lease term through April 2021.

11

Table of Contents

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

(UNAUDITED)

(ROUNDED)

RECENT ACCOUNTING PRONOUNCEMENTS

The Company does not expect the adoption of recently issued accounting pronouncements to have a potential impact on the Company’s results of operations, financial position or cash flow.

Leases: In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) and subsequent amendments to the initial guidance: ASU 2017-13, ASU 2018-10, ASU 2018-11, ASU 2018-20 and ASU 2019-01 (collectively, Topic 842). Topic 842 requires companies to generally recognize on the balance sheet operating and financing lease liabilities and corresponding right-of-use assets. The Company early adopted Topic ASC 842 using the effective date of January 1, 2019 as the date of our initial application of the standard. The Company used the new transition election to not restate comparative periods and elected the package of practical expedients upon adoption, which permits the Company to not reassess under the new standard the Company’s prior conclusions about lease identification, lease classification and initial direct costs. Consequently, financial information for the comparative periods will not be updated. Upon adoption, there was no material impact to the financial statements.

Stock Based Compensation: In June 2018, FASB issued ASU No. 2018-07, Compensation – Stock Compensation (Topic 718),Improvements to Nonemployee Share Based Payment Accounting. The amendments in this Update expand the scope of stock compensation to include share-based payment transactions for acquiring goods and services from nonemployees. The guidance in this Update does not apply to transactions involving equity instruments granted to a lender or investor that provides financing to the issuer. The guidance is effective for fiscal years beginning after December 31, 2018 including interim periods within the fiscal year. The Company adopted with an effective date of January 1, 2019. Upon adoption, there was no material impact to the financial statements.

There are no other recent accounting pronouncements that are expected to have a material impact on the condensed consolidated financial statements.

NOTE 4 – INVESTMENT IN IMAGION BIOSYSTEMS

As of September 30, 2019, the Company owns 63,999,476 shares of Imagion Biosystems (“Imagion”), resulting in a noncontrolling interest of Imagion’s issued and outstanding common stock. Initially, the Company held approximately 31% of Imagion’s total issued and outstanding common stock and was later was decreased to approximately 19%. Based upon Imagion’s trading price on September 30, 2019, approximately $0.033 per share, the fair value of the Imagion shares was approximately $2,114,000. During the nine months ended September 30, 2019, the Company recorded an unrealized gain in its investment of $764,000.

During the nine months ended September 30, 2019, the Company sold 100,000 shares of Imagion and received cash proceeds of $2,480.

NOTE 5 – NOTES PAYABLE

On March 11, 2019, the Company received a loan for $50,000 and entered into a promissory note and security agreement with a third party. The loan was secured with ECAP-C machines. The due date of the loan was the earlier of April 30, 2019 or the closing of the transaction with the third party. Interest shall accrue at a rate of 6% per annum from April 11, 2019 until paid in full.

On May 1, 2019, the transaction closed and agreements were executed. The Company repaid the $50,000 upon closing of the transaction.

12

Table of Contents

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

(UNAUDITED)

(ROUNDED)

NOTE 6 – LICENSE AGREEMENT

On May 1, 2019, the Company, entered into an agreement with a non-affiliated third party (“Third Party”), providing for an exclusive license by the Company of its ECAP technology to the Third Party for a term of 17 years unless terminated sooner, a sublicense by the Company to the Third Party of its rights under that certain Exclusive Field-of-Use Patent License Agreement dated January 5, 2009 entered with The Los Alamos National Laboratory for a term until the expiration of the last valid claim to expire of the patents pursuant to such agreement and the sale by the Company of ECAP-C machines to the Third party. As part of the above license agreements, the Company will receive royalty payments, including minimum payments, based on a percentage of the Third Party’s sales. Royalties will be 10% on gross sales of licensed dental products and average of 5% on all other sales of licensed products.

During the nine months ended September 30, 2019, the Company received $50,000 as a minimum royalty payment.

NOTE 7 – REVENUE

During the nine months ended September 30, 2019, the Company recorded revenue of $22,000 for which the services were performed and completed in 2018, but the Company performed an assessment and determined the collectability was not reasonably assured and did not record as revenue in 2018 per ASC 605. The original contract was dated in 2017. In 2019, the Company collected on the invoice and recorded revenue upon receipt of the funds.

NOTE 8 – COMMITMENTS AND CONTINGENCIES

As of September 30, 2019, we did not have any known commitments or contingencies.

Legal matter contingencies

The Company believes, based on current knowledge and after consultation with counsel, that it is not currently party to any material pending proceedings, individually or in the aggregate, the resolution of which would have a material effect on the Company. Provisions for losses are established in accordance with ASC 450, “Contingencies” when warranted. Once established, such provisions are adjusted when there is more information available of when an event occurs requiring a change.

NOTE 9 – STOCKHOLDERS’ EQUITY (DEFICIT)

During the three months ended June 30, 2019, the Company issued 24,000,000 shares of common stock to its board of directors for services valued at $360,000. The shares were valued based on the market price of the Company’s common shares of $0.015 on the grant date.

During the three months ended June 30, 2019, the Company issued 500,000 options to its advisors for services valued at approximately $7,000. The options are exercisable at $0.015 and have a life of 5 years.

NOTE 10 – SUBSEQUENT EVENTS

In accordance with ASC 855-10, the Company has analyzed its operations subsequent to September 30, 2019 to the date these financial statements were issued, and there were no material subsequent events to disclose in these financial statements.

13

Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

Forward Looking Statements

This Form 10-Q contains “forward-looking” statements including statements regarding our expectations of our future operations. For this purpose, any statements contained in this Form 10-Q that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “estimate,” or “continue” or comparable terminology are intended to identify forward-looking statements. These statements by their nature involve substantial risks and uncertainties, and actual results may differ materially depending on a variety of factors, many of which are not within our control. These factors include, but are not limited to, economic conditions generally and in the industries in which we may participate. In addition, these forward-looking statements are subject, among other things, to our successful completion of the research and development of our technologies; successful commercialization of our technologies; successful protection of our patents; and effective significant industry competition from various entities whose research and development, financial, sales and marketing and other capabilities far exceeds ours. In light of these risks and uncertainties, you are cautioned not to place undue reliance on these forward-looking statements. Except as required by law, we undertake no obligation to announce publicly revisions we make to these forward-looking statements to reflect the effect of events or circumstances that may arise after the date of this report.

OVERVIEW

Manhattan Scientifics, Inc. (the “Company” or “Manhattan Scientifics”), a Delaware corporation, was established on July 31, 1992 and has one operating wholly-owned subsidiary: Metallicum, Inc., (“Metallicum”). Manhattan Scientifics is focused on technology transfer and commercialization of these transformative technologies.

The Company operates as a technology incubator that seeks to acquire, develop and commercialize life-enhancing technologies in various fields, with emphasis in the areas of nanotechnology. Nanotechnology is the use and manipulation of matter on an atomic and molecular scale. To achieve this goal, the Company continues to identify emerging technologies through strategic alliances with scientific laboratories, educational institutions, scientists and leaders in industry and government. The Company and its executives have a long-standing relationship with Los Alamos Laboratories in New Mexico.

In June 2008, we acquired Metallicum and its licensed patented technology. We entered into a stock purchase agreement with Metallicum to acquire all of the outstanding capital in exchange for 15,000,000 restricted shares of our common stock. An additional 15,000,000 shares of our common stock will be payable to Metallicum in the event of meeting certain milestones. At December 31, 2011, one milestone was met. Metallicum was granted an exclusive license by The Los Alamos National Laboratory on patents related to nanostructured metals. In September 2009, we entered into a technology transfer agreement and sale with Carpenter Technology Corporation, (“Carpenter”) wherein Carpenter was to fully develop, manufacture and market a new class of high strength metals. On February 11, 2015, the Company and Carpenter entered into a Settlement Agreement and Mutual Release pursuant to which the parties provided a full release of one another, Carpenter paid the Company $8,000,000, Carpenter transferred to the Company all intellectual and physical property that was part of the original agreement, Carpenter agreed to provide follow-on technical assistance and Carpenter provided a list of all customers and contacts.

On May 31, 2011, we entered into an Agreement and Plan of Reorganization to acquire Senior Scientific. The total purchase price was 21,668,000 restricted shares of our common stock (less 7,667,000 shares previously issued pursuant to an option agreement). As a result of this acquisition, Senior Scientific owned patented technologies that can use biosafe nanoparticles and sensitive magnetic sensors to detect and measure cancer cells in biopsies or in the human body with the potential to transform how cancer is detected and treated. On November 17, 2016, Senior Scientific merged with and into Imagion, a Nevada company. Following the merger, Imagion held all of the liabilities, obligations and assets of Senior Scientific and the Company continued as the sole equity holder of Imagion. On November 29, 2016, the Company announced a plan to have Imagion pursue an IPO and listing on the Australian Stock Exchange (ASX). As of September 30, 2019, Manhattan Scientifics presently owns 63,999,476 shares of Imagion, with a fair market value of approximately $2,114,000, based upon the closing price per share of Imagion common stock on the Australian Stock Exchange. The Company accounts for its investment in Imagion in accordance with ASC 825-10 and elected fair value option. We initially held 31% of the total issued and outstanding shares of Imagion and had one seat on the Board of Directors of Imagion. The guidance allows entities to elect to measure certain financial assets and financial liabilities (as well as certain nonfinancial instruments that are similar to financial instruments) at fair value. Investments over which an investor has the ability to exercise significant influence are eligible for the fair value option as they represent recognized financial assets. When the fair value option is elected for an instrument, all subsequent changes in fair value for that instrument are reported in earnings. As of September 30, 2019, we hold approximately 19% of the total issued and outstanding shares of Imagion and no longer have a seat on the Board of Directors of Imagion.

14

Table of Contents

On May 1, 2019, Manhattan Scientifics, Inc., a Delaware corporation (the “Company”), and Metallicum, Inc., a wholly-owned subsidiary of the Company, entered into an Overarching Agreement with a non-affiliated third party (“Third Party”), providing for an exclusive license by the Company of its ECAP technology to the Third Party for a term of 17 years unless terminated sooner, a sublicense by the Company to the Third Party of its rights under that certain Exclusive Field-of-Use Patent License Agreement dated January 5, 2009 entered with The Los Alamos National Laboratory for a term until the expiration of the last valid claim to expire of the patents pursuant to such agreement and the sale by the Company of ECAP-C machines to the Third party. As part of the above license agreements, the Company will receive royalty payments, including minimum payments, based on a percentage of the Third Party’s sales. The Company anticipates royalty income as the nanotitanium is commercialized for use in medial prosthetics. Royalties will be 10% on sales of licensed dental products and an average of 5% in all other sales of licensed products.

The global prosthetics and orthotics market size is estimated at $8.15 billion. The Company’s client serves multiple markets including vascular therapy, cardiac rhythm management, endoscopy, orthopedics, dental and neuromodulation.

RESULTS OF OPERATIONS

THREE MONTHS ENDED SEPTEMBER 30, 2019 COMPARED TO THREE MONTHS ENDED SEPTEMBER 30, 2018

REVENUE. Revenue was $22,000 for the three months ended September 30, 2019 compared with $0 for the three months ended September 30, 2018. The revenue consists of fees from completed services in 2018, however collected in 2019.

GENERAL AND ADMINISTRATIVE. General and administrative expenses consist of consultants, contractors, accounting, legal, travel, rent, telephone and other day-to-day operating expenses. General and administrative expenses were $187,000 for the three months ended September 30, 2019 compared with $322,000 for the three months ended September 30, 2018. The primary decrease in general and administrative expenses was the result of the decrease in consulting and legal expenses.

RESEARCH AND DEVELOPMENT. Research and development was $3,000 for the three months ended September 30, 2019 compared with $0 for the three months ended September 30, 2018. The decrease in research and development was based on the departure of its chief scientist and the Company was in the process of licensing its technology a third party.

OTHER INCOME AND (EXPENSES). Total other income for the three months ended September 30, 2019 totaled $1,397,000 compared to $646,000 for the three months ended September 30, 2018. This is primarily attributable to the gain on fair value adjustments of its investment in Imagion during the period.

NET INCOME. During the three months ended September 30, 2019, the Company incurred a net income of $1,229,000, compared to a net loss of $324,000 for the three months ended September 30, 2018. The change from a net loss to net income is mainly attributable to the change in the fair valuation of our investment in Imagion.

NINE MONTHS ENDED SEPTEMBER 30, 2019 COMPARED TO NINE MONTHS ENDED SEPTEMBER 30, 2018

REVENUE. Revenue was $72,000 for the three months ended September 30, 2019 compared with $0 for the three months ended September 30, 2018. A portion of the revenue consists of fees from completed services in 2018, however collected in 2019. The remaining $50,000 of revenue is from the minimum license fee for 2019.

GENERAL AND ADMINISTRATIVE. General and administrative expenses consist of consultants, contractors, accounting, legal, travel, rent, telephone and other day-to-day operating expenses. General and administrative expenses were $945,000 for the nine months ended September 30, 2019 compared with $1,089,000 for the nine months ended September 30, 2018. The primary decrease in general and administrative expenses was the result of the decrease in consulting and legal expenses and asset impairment happened in 2018 and didn’t occur in 2019.

RESEARCH AND DEVELOPMENT. Research and development was $6,000 for the nine months ended September 30, 2019 compared with $52,000 for the nine months ended September 30, 2018. The decrease in research and development was based on the departure of its chief scientist and the Company was in the process of licensing its technology a third party.

OTHER INCOME AND (EXPENSES). Total other income (expense) for the nine months ended September 30, 2019 totaled $764,000 compared to ($2,727,000) for the nine months ended September 30, 2018. This is primarily attributable to the gain (loss) on fair value adjustments of its investment in Imagion during the period.

NET (LOSS). During the nine months ended September 30, 2019, the Company incurred a net loss of $115,000, compared to a net loss of $4,717,000 for the nine months ended September 30, 2018. The decline in the net loss is mainly attributable to the reduction in the loss on fair value adjustment.

15

Table of Contents

LIQUIDITY AND CAPITAL RESOURCES

Stockholders’ equity totaled $102,000 on September 30, 2019 and the working capital deficit was $1,565,000 on such date. We had a increase of $57,000 in cash and cash equivalents for the nine months ended September 30, 2019.

Based upon current projections, our principal cash requirements for the next 12 months consists of (1) fixed expenses, including payroll, investor relations services, public relations services, bookkeeping services, consultant services, and rent; and (2) variable expenses, including technology research and development, milestone payments and intellectual property protection, and additional scientific consultants. As of September 30, 2019, we had $144,000 in cash. We believe our current cash position is not sufficient to maintain our operations for the next twelve months. Accordingly, we will need to engage in equity or debt financings to secure additional funds. If we raise additional funds through future issuances of equity or convertible debt securities, our existing stockholders could suffer significant dilution, and any new equity securities we issue could have rights, preferences and privileges superior to those of holders of our common stock. Any debt financing that we secure in the future could involve restrictive covenants relating to our capital raising activities and other financial and operational matters, which may make it more difficult for us to obtain additional capital and to pursue business opportunities, including potential acquisitions. We may not be able to obtain additional financing on terms favorable to us, if at all. If we are unable to obtain adequate financing or financing on terms satisfactory to us when we require it, our ability to continue to support our business growth and to respond to business challenges could be impaired, and our business may be harmed.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

Our discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amount of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. A significant estimate includes the carrying value of our patents, fair value of our common stock, assumptions used in calculating the value of stock options, depreciation and amortization.

Impairment of Long-Lived Assets:

We assess the impairment of our long-lived assets periodically in accordance with Financial Accounting Standards Board ("FAS") Accounting Standard Codification (“ASC”) Topic 10. Whenever events or changes in circumstances indicate that the carrying amounts of long-lived assets may not be recoverable, we will compare undiscounted net cash flows estimated to be generated by those assets to the carrying amount of those assets. When these undiscounted cash flows are less than the carrying amounts of the assets, we will record impairment losses to write the asset down to fair value, measured by the discounted estimated net future cash flows expected to be generated from the assets. To date there has been no impairment.

Investment in Imagion:

16

Table of Contents

Management determined that it was appropriate to carry its investment in Imagion at fair value because the investment is traded on the Australian stock exchange and has daily trading activity and is a better indicator of value. The investments are re-measured at the end of each quarter based on the trading price and converted from AUD to USD. Any change in the value is reported on the income statement as an gain or loss on the fair value adjustment of investments.

License Agreements

In 2008, the Company obtained licenses to the rights of certain patents regarding nano-structured materials developed by another company as a result of the acquisition of Metallicum. The purchase price paid for these licenses was $305,000, which represents its fair value. The Company obtained an exclusive license on two patents and a non-exclusive license on the third patent. The value attributable to license agreements is being amortized over the period of its estimated benefit period of 10 years. Under the terms of the agreement, the Company may be required to pay royalties, as defined, to the licensors.

In 2009, the Company entered into a patent license agreement with Los Alamos National Security LLC for the exclusive use of certain technology relating to the manufacture and application of nanostructuring metals and alloys. The value attributable to license agreements is being amortized over the period of its estimated benefit period of 10 years. Under the terms of the agreement the Company is required to pay an annual license fee of $10,000 and, may be required to pay royalties, as defined, to the licensors.

Assets Held for Sale

Non-current assets are classified as held for sale if it is highly probably that they will be recovered primarily through sale rather than through continuing use.

Immediately before classification as held for sale, the assets are remeasured at the lower of their carrying amount and fair value less costs to sell. Any impairment loss on initial classification as held for sale and subsequent gains and losses on reameasurement are recognized in profit or loss. Gains are not recognized in excess of any cumulative impairment loss.

Revenue Recognition

OFF BALANCE SHEET ARRANGEMENTS

We have not entered into any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations liquidity, capital expenditures or capital resources and would be considered material to investors.

17

Table of Contents

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

As a smaller reporting company, we are not required to include disclosure under this item.

ITEM 4. CONTROLS AND PROCEDURES

(a) Evaluation of Disclosure Controls and Procedures

We conducted an evaluation under the supervision and with the participation of our management, of the effectiveness of the design and operation of our disclosure controls and procedures. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities and Exchange Act of 1934, as amended (“Exchange Act”), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by the company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission's rules and forms. Disclosure controls and procedures also include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company's management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. Based on this evaluation, our principal executive and principal financial officers concluded as of September 30, 2019 that our disclosure controls and procedures were not effective at the reasonable assurance level due to the material weaknesses in our internal controls over financial reporting discussed immediately below.

Identified Material Weakness

A material weakness in our internal control over financial reporting is a control deficiency, or combination of control deficiencies, that results in more than a remote likelihood that a material misstatement of the financial statements will not be prevented or detected.

Management identified the following material weakness during its assessment of internal controls over financial reporting:

Resources: We had one full-time employee in general management and no full-time employees with the requisite expertise in the key functional areas of finance and accounting. As a result, there is a lack of proper segregation of duties necessary to insure that all transactions are accounted for accurately and in a timely manner.

Written Policies & Procedures: We need to prepare written policies and procedures for accounting and financial reporting to establish a formal process to close our books monthly on an accrual basis and account for all transactions, including equity transactions, and prepare, review and submit SEC filings in a timely manner.

Audit Committee: We do not have, and are not required, to have an audit committee. An audit committee would improve oversight in the establishment and monitoring of required internal controls and procedures.

(b) Changes In Internal Control Over Financial Reporting

During the quarter ended September 30, 2019, the Company prepared written policies and procedures for accounting and financial reporting to establish a formal process to close our books monthly on an accrual basis and account for all transactions, including equity transactions. There were no other changes in our internal controls over financial reporting during this fiscal quarter that materially affected, or is reasonably likely to have a materially affect, on our internal control over financial reporting.

18

Table of Contents

PART II – OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

We are subject from time to time to litigation, claims and suits arising in the ordinary course of business. As of September 30, 2019, we were not a party to any material litigation, claim or suite whose outcome could have a material effect on our financial statements.

ITEM 1A. RISK FACTORS

An investment in the Common Stock involves a high degree of risk. In addition to the other information in this report, the following risk factors should be considered carefully in evaluating the Company and our business. If you decide to buy our securities, you should be able to afford a complete loss of your investment.

WE MAY NOT BE ABLE TO SUCCESSFULLY DEVELOP AND COMMERCIALIZE OUR NEW TECHNOLOGIES WHICH WOULD RESULT IN CONTINUED LOSSES.

We are currently developing new technologies and a commercial product. We have generated our first revenues but we are unable to project when we will again generate significant revenue or achieve regular profitability, if at all. As is the case with any new technology, we expect the development process to continue. We cannot assure that our resources will be able to develop and commercialize our technology fast enough to meet market requirements. We can also not assure that our technology will gain market acceptance and that we will be able to overcome obstacles, such as potential FDA approvals. The failure to successfully develop and commercialize the technologies would result in continued losses and may require us to curtail operations.

THE SUCCESS OF OUR BUSINESS MAY REQUIRE CONTINUED FUNDING. IF WE CANNOT RAISE THE MONEY WE NEED TO SUPPORT OUR OPERATIONS UNTIL WE EARN SIGNIFICANT REVENUES, WE MAY BE REQUIRED TO CURTAIL OR TO CEASE OUR OPERATIONS AND YOU COULD LOSE YOUR ENTIRE INVESTMENT.

Our ability to develop our business depends upon our receipt of money to continue our operations while we introduce our products and a market for them develops. If this funding is not received as needed, it is unlikely that we could continue our business, in which case you would lose your entire investment. Our ability to access the capital markets has been hindered generally by the general difficult economic climate, beginning in 2008, for small technology concept companies, without significant revenues or earnings.

To the extent that we need additional funding, we cannot assure you that such financing will be available to us when needed, on commercially reasonable terms, or at all. If we are unable to obtain additional financing, we may be required to curtail the commercialization of our products and possibly cease our operations.

OUR ABILITY TO EFFECTUATE OUR BUSINESS MODEL MAY BE LIMITED, WHICH WOULD ADVERSELY EFFECT OUR BUSINESS AND FINANCIAL CONDITIONS.

Our future performance will depend to a substantial degree upon our ability to effectuate and generate revenues from our licensing and royalty business model. As a result, we may continue to incur substantial operating losses until such time as we are able to generate revenues from the sale or license of our products. There can be no assurance that businesses and customers will adopt our technology and products, or that businesses and prospective customers will agree to pay for or license our products. In the event that we are not able to significantly increase the number of customers that purchase or license our products, or if we are unable to charge the necessary prices or license fees, our financial condition and results of operations will be materially and adversely affected.

Table of Contents

WE MAY FACE STRONG COMPETITION FROM LARGER, ESTABLISHED COMPANIES.

We likely will face intense competition from other companies, both globally and within the United States, in the development of our cancer detection technology and nano-metal technologies, virtually all of which can be expected to have longer operating histories, greater name recognition, larger installed customer bases and significantly more financial resources and research and development facilities than Manhattan Scientifics. There can be no assurance that developments by our current or potential competitors will not render our proposed products obsolete.

WE MAY NOT BE ABLE TO ADEQUATELY PROTECT OUR INTELLECTUAL PROPERTY OR WE COULD BECOME INVOLVED IN LITIGATION WITH OTHERS REGARDING OUR INTELLECTUAL PROPERTY. EITHER OF THESE EVENTS COULD HAVE A MATERIAL ADVERSE EFFECT ON OUR BUSINESS.

We rely on a combination of intellectual property law, nondisclosure, trade secret and other contractual and technical measures to protect our proprietary right. Our success will depend, in part, on our technology’s commercial viability and on the strength of our intellectual property rights. However, we cannot assure you that these provisions will be adequate to protect our intellectual property. In addition, the laws of certain foreign countries do not protect intellectual property rights to the same extent as the laws of the United States.

Although we believe that our intellectual property does not infringe upon the proprietary rights of third parties, competitors may claim that we have infringed on their products.

We could incur substantial costs in defending ourselves in suits brought against us for alleged infringement of another party’s intellectual property rights as well as in enforcing our rights against others, and if we are found to infringe, the manufacture, sale and use of our or our customers’ or partners’ products could be enjoined. Any claims against us, with or without merit, would likely be time-consuming, requiring our management team to dedicate substantial time to addressing the issues presented. Furthermore, the parties bringing claims may have greater resources than we do.

OUR MANAGEMENT IS ABLE TO EXERCISE SIGNIFICANT INFLUENCE OVER ALL MATTERS REQUIRING SHAREHOLDER APPROVAL.

Our existing directors and executive officers are the beneficial owners of approximately 25% of the outstanding shares of common stock, excluding stock options and warrants. As a result, our existing directors, executive officers, principal shareholders and their respective affiliates, if acting together, would be able to exercise significant influence over all matters requiring shareholder approval, including the election of directors and the approval of significant corporate transactions. Such concentration of ownership may also have the effect of delaying or preventing a change in control of our company.

THE TRADING PRICE OF OUR COMMON STOCK MAY DECREASE DUE TO FACTORS BEYOND OUR CONTROL.

The trading price of our common stock is subject to significant fluctuations in response to numerous factors, including without limitation:

	·	variations in anticipated or actual results of operations;

	·	announcements of new products or technological innovations by us or our competitors;

	·	changes in earnings estimates of operational results by analysts;

	·	inability of market makers to combat short positions on the stock;

	·	an overall downturn in the financial markets and stock markets;

	·	the use of stock to pay employees and consultants if sufficient working capital is not available;

	·	inability of the market to absorb large blocks of stock sold into the market; and

	·	developments or disputes concerning our intellectual property.

20

Table of Contents

Moreover, the stock market from time-to-time has experienced extreme price and volume fluctuations, which have particularly affected the market prices for small technology companies without significant revenues. These broad market fluctuations may adversely affect the market price of our Common Stock. If our shareholders sell substantial amounts of their common stock in the public market, the price of our common stock could fall. These sales also might make it more difficult for us to sell equity or equity-related securities in the future at a price we deem appropriate.

WE HAVE NOT PAID CASH DIVIDENDS AND IT IS UNLIKELY THAT WE WILL PAY CASH DIVIDENDS IN THE FORESEEABLE FUTURE.

We plan to use all of our earnings, to the extent we have significant earnings, to fund our operations. We do not plan to pay any cash dividends in the foreseeable future. We cannot guarantee that we will, at any time, generate sufficient surplus cash that would be available for distribution as a dividend to the holders of our Common Stock. You should not expect to receive cash dividends on our Common Stock.

WE MAY NOT HAVE SUFFICIENT CAPITAL TO RUN OUR OPERATIONS.

If we are unable to obtain further financing, it may jeopardize our ability to continue our operations. To the extent that additional capital is raised through the sale of equity and/or convertible debt securities, the issuance of such securities could result in dilution to our shareholders and/or increased debt service commitments. If adequate funds are not available, we may be unable to sufficiently develop or maintain our existing operations.

WE HAVE THE ABILITY TO ISSUE ADDITIONAL SHARES OF OUR COMMON STOCK WITHOUT ASKING FOR SHAREHOLDER APPROVAL, WHICH COULD CAUSE YOUR INVESTMENT TO BE DILUTED.

Our Certificate of Incorporation currently authorizes the Board of Directors to issue up to 950,000,000 shares of Common Stock and 1,000,000 shares of Preferred Stock. The power of the Board of Directors to issue shares of Common Stock or warrants or options to purchase shares of Common Stock is generally not subject to shareholder approval. Accordingly, any additional issuance of our Common Stock may have the effect of further diluting your investment.

We require substantial working capital to fund our business. If we raise additional funds through the issuance of equity, equity-related or convertible debt securities, those securities may have rights, preferences or privileges senior to those of the holders of our Common Stock. The issuance of additional Common Stock or securities convertible into Common Stock by our management will also have the effect of further diluting the proportionate equity interest and voting power of holders of our Common Stock.

LIMITED PUBLIC MARKET FOR OUR COMMON STOCK MAY AFFECT OUR SHAREHOLDERS' ABILITY TO SELL OUR COMMON STOCK.

Our Common Stock currently is quoted on the OTCQB operated by OTC Markets, which is generally considered to be a less efficient market than national exchanges. Consequently, the liquidity of our securities could be impaired, not only in the number of securities which could be bought and sold, but also through SEC regulations, delays in the timing of transactions, difficulties in obtaining price quotations, reduction in security analysts' and the new media's coverage of us, if any, and lower prices for our securities than might otherwise be attained. This circumstance could have an adverse effect on the ability of an investor to sell any shares of our common stock as well as on the selling price for such shares. In addition, the market price of our common stock may be significantly affected by various additional factors, including, but not limited to, our business performance, industry dynamics or changes in general economic conditions.

Table of Contents

APPLICABILITY OF "PENNY STOCK RULES" TO BROKER-DEALER SALES OF OUR COMMON STOCK COULD HAVE A NEGATIVE EFFECT ON THE LIQUIDITY AND MARKET PRICE OF OUR COMMON STOCK.

A penny stock is generally a stock that is not listed on national securities exchange and is quoted on the "pink sheets" or on the OTC Bulletin Board, has a price per share of less than $5.00 and is issued by a company with net tangible assets less than $5 million.

The penny stock trading rules impose additional duties and responsibilities upon broker-dealers and salespersons effecting purchase and sale transactions in Common Stock and other equity securities, including determination of the purchaser's investment suitability, delivery of certain information and disclosures to the purchaser, and receipt of a specific purchase agreement before effecting the purchase transaction.

Many broker-dealers will not affect transactions in penny stocks, except on an unsolicited basis, in order to avoid compliance with the penny stock trading rules. When our Common Stock is subject to the penny stock trading rules, such rules may materially limit or restrict the ability to resell our Common Stock, and the liquidity typically associated with other publicly traded equity securities may not exist.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

Not applicable.

22

Table of Contents

ITEM 6. EXHIBITS

Index to Exhibits

31.1		Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1		Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

EX-101.INS**		XBRL Instance Document

EX-101.SCH**		XBRL Taxonomy Extension Schema Document

EX-101.CAL**		XBRL Taxonomy Extension Calculation Linkbase

EX-101.DEF**		XBRL Taxonomy Extension Definition Linkbase

EX-101.LAB**		XBRL Taxonomy Extension Labels Linkbase

EX-101.PRE**		XBRL Taxonomy Extension Presentation Linkbase

_________________

** XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

Table of Contents

SIGNATURES

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 19th day of November, 2019.

	MANHATTAN SCIENTIFICS, INC.

	By:	/s/ Emmanuel Tsoupanarias
	Name:	Emmanuel Tsoupanarias
	Title:	Chief Executive Officer (Principal Executive, Financial and Accounting Officer)

EX-31.1 2 mhtx_ex311.htm CERTIFICATION mhtx_ex311.htm

EXHIBIT 31.1

CERTIFICATIONS

I, Emmanuel Tsoupanarias, certify that:

1.	I have reviewed this quarterly report on Form 10-Q for the period ended September 30, 2019 (the “report”) of Manhattan Scientifics, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a.	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b.	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c.	Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d.	Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.	The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

	a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

	b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


Date: November 19, 2019	By:	/s/ Emmanuel Tsoupanarias
		Emmanuel Tsoupanarias
		Chief Executive Officer
		(principal executive, financial and accounting officer)

EX-32.1 3 mhtx_ex321.htm CERTIFICATION mhtx_ex321.htm

EXHIBIT 32.1

CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), the undersigned officer of Manhattan Scientifics, Inc., a Delaware corporation (the “Company”), does hereby certify, to the best of his knowledge, that:

	(1)	The Quarterly Report of Form 10-Q for the period ending September 30, 2019 (the “Report”) of the Company complies in all material respects with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

	(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.


Date: November 19, 2019	By:	/s/ Emmanuel Tsoupanarias
		Emmanuel Tsoupanarias
		Chief Executive Officer
		(principal executive, financial and accounting officer)

EX-101.INS 4 mhtx-20190930.xml XBRL INSTANCE DOCUMENT 0001099132 2019-01-01 2019-09-30 0001099132 2019-11-19 0001099132 2019-09-30 0001099132 2018-12-31 0001099132 mhtx:SeriesDconvertiblepreferredStockMember 2019-09-30 0001099132 mhtx:SeriesDconvertiblepreferredStockMember 2018-12-31 0001099132 mhtx:ClassAConvertiblePreferredStockMember 2019-09-30 0001099132 mhtx:ClassBConvertiblePreferredStockMember 2019-09-30 0001099132 mhtx:ClassCRedeemableConvertiblePreferredStockMember 2019-09-30 0001099132 mhtx:ClassAConvertiblePreferredStockMember 2018-12-31 0001099132 mhtx:ClassBConvertiblePreferredStockMember 2018-12-31 0001099132 mhtx:ClassCRedeemableConvertiblePreferredStockMember 2018-12-31 0001099132 2019-07-01 2019-09-30 0001099132 2018-07-01 2018-09-30 0001099132 2018-01-01 2018-09-30 0001099132 mhtx:PreferredStockSeriesBMember 2017-12-31 0001099132 mhtx:PreferredStockSeriesBMember 2018-01-01 2018-03-31 0001099132 mhtx:PreferredStockSeriesBMember 2018-03-31 0001099132 us-gaap:CommonStockMember 2017-12-31 0001099132 us-gaap:CommonStockMember 2018-01-01 2018-03-31 0001099132 us-gaap:CommonStockMember 2018-03-31 0001099132 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001099132 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0001099132 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0001099132 us-gaap:RetainedEarningsMember 2017-12-31 0001099132 us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0001099132 us-gaap:RetainedEarningsMember 2018-03-31 0001099132 2017-12-31 0001099132 2018-01-01 2018-03-31 0001099132 2018-03-31 0001099132 mhtx:PreferredStockSeriesBMember 2018-04-01 2018-06-30 0001099132 mhtx:PreferredStockSeriesBMember 2018-06-30 0001099132 us-gaap:CommonStockMember 2018-04-01 2018-06-30 0001099132 us-gaap:CommonStockMember 2018-06-30 0001099132 us-gaap:AdditionalPaidInCapitalMember 2018-04-01 2018-06-30 0001099132 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0001099132 us-gaap:RetainedEarningsMember 2018-04-01 2018-06-30 0001099132 us-gaap:RetainedEarningsMember 2018-06-30 0001099132 2018-04-01 2018-06-30 0001099132 2018-06-30 0001099132 mhtx:PreferredStockSeriesBMember 2018-07-01 2018-09-30 0001099132 mhtx:PreferredStockSeriesBMember 2018-09-30 0001099132 us-gaap:CommonStockMember 2018-07-01 2018-09-30 0001099132 us-gaap:CommonStockMember 2018-09-30 0001099132 us-gaap:AdditionalPaidInCapitalMember 2018-07-01 2018-09-30 0001099132 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0001099132 us-gaap:RetainedEarningsMember 2018-07-01 2018-09-30 0001099132 us-gaap:RetainedEarningsMember 2018-09-30 0001099132 2018-09-30 0001099132 mhtx:PreferredStockSeriesBMember 2018-12-31 0001099132 mhtx:PreferredStockSeriesBMember 2019-01-01 2019-03-31 0001099132 mhtx:PreferredStockSeriesBMember 2019-03-31 0001099132 us-gaap:CommonStockMember 2018-12-31 0001099132 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001099132 us-gaap:CommonStockMember 2019-03-31 0001099132 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001099132 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001099132 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001099132 us-gaap:RetainedEarningsMember 2018-12-31 0001099132 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001099132 us-gaap:RetainedEarningsMember 2019-03-31 0001099132 2019-01-01 2019-03-31 0001099132 2019-03-31 0001099132 mhtx:PreferredStockSeriesBMember 2019-04-01 2019-06-30 0001099132 mhtx:PreferredStockSeriesBMember 2019-06-30 0001099132 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0001099132 us-gaap:CommonStockMember 2019-06-30 0001099132 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0001099132 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001099132 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001099132 us-gaap:RetainedEarningsMember 2019-06-30 0001099132 2019-04-01 2019-06-30 0001099132 2019-06-30 0001099132 mhtx:PreferredStockSeriesBMember 2019-07-01 2019-09-30 0001099132 mhtx:PreferredStockSeriesBMember 2019-09-30 0001099132 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0001099132 us-gaap:CommonStockMember 2019-09-30 0001099132 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0001099132 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001099132 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0001099132 us-gaap:RetainedEarningsMember 2019-09-30 0001099132 mhtx:LosAlamosNationalSecurityLLCMember mhtx:PatentLicenseAgreementMember 2009-12-31 0001099132 2008-01-01 2008-12-31 0001099132 mhtx:MetallicumMember mhtx:LicenseAgreementsMember 2008-01-01 2008-12-31 0001099132 2009-01-01 2009-12-31 0001099132 mhtx:MetallicumMember mhtx:LicenseAgreementsMember 2008-12-31 0001099132 mhtx:LosAlamosNationalSecurityLLCMember mhtx:PatentLicenseAgreementMember 2009-01-01 2009-12-31 0001099132 mhtx:ImagionBiosystemsIncMember 2019-09-30 0001099132 mhtx:ImagionBiosystemsIncMember 2019-01-01 2019-09-30 0001099132 2019-05-01 0001099132 2019-04-01 2019-04-11 0001099132 mhtx:SecurityAgreementMember 2019-03-01 2019-03-11 0001099132 srt:DirectorMember 2019-04-01 2019-06-30 0001099132 srt:DirectorMember 2019-01-01 2019-06-30 0001099132 2019-01-01 2019-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure MANHATTAN SCIENTIFICS INC 0001099132 10-Q false --12-31 true false false Yes 2019-09-30 Non-accelerated Filer Q3 2019 557781064

144000

87000

6000

11000

300000

450000

98000

2117000

1354000

6000

1200000

600000

2000

3175000

2660000

237000

221000

1778000

1531000

2015000

1752000

2015000

1752000

1058000

558000

534000

67632000

67289000

-68088000

-67973000

102000

-150000

3175000

2660000

182525

250000

49999

14000

105671

.001

447804

950000000

533781064

557781064

533781064

557781064

22000

72000

7000

187000

322000

945000

1089000

3000

6000

52000

842000

190000

322000

951000

1990000

-168000

-322000

-879000

-1990000

1397000

646000

764000

-2727000

1229000

324000

-115000

-4717000

557781064

533781064

546528317

533781064

0.00

-0.00

-0.01

597886064

584579246

546528317

533781064

0.00

-0.00

-0.01

49999

533781064

534000

533781064

534000

67289000

-59662000

-2828000

-62490000

8161000

-2828000

5333000

49999

533781064

534000

67289000

-2213000

-64703000

-2213000

3120000

49999

533781064

534000

67289000

324000

-64379000

324000

3444000

49999

533781064

534000

533781064

534000

67289000

-67973000

-436000

-68409000

-436000

-586000

49999

557781064

558000

67632000

-908000

-69317000

-908000

-1127000

49999

557781064

558000

67632000

1229000

-68088000

1229000

7000 7000 24000000 24000 336000 360000

360000

7000

1000

496000

-764000

2727000

5000

7000

263000

118000

-243000

-527000

-2000

300000

500000

2000

300000

500000

57000

-27000

269000

242000

<div style="font: 10pt TIMES NEW ROMAN; text-align: justify;"><div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN">The foregoing unaudited interim financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions for Form 10-Q and Regulation S-X as promulgated by the Securities and Exchange Commission (“SEC”). Accordingly, these financial statements do not include all of the disclosures required by generally accepted accounting principles in the United States of America for complete financial statements. These unaudited interim financial statements should be read in conjunction with the audited financial statements and the notes thereto included on Form 10-K for the year ended December 31, 2018, filed on March 29, 2019. In the opinion of management, the unaudited interim financial statements furnished herein include all adjustments, all of which are of a normal recurring nature, necessary for a fair statement of the results for the interim period presented. The preparation of financial statements in accordance with generally accepted accounting principles in the United States of America requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published, and the reported amounts of revenues and expenses during the reporting period. Uncertainties with respect to such estimates and assumption are inherent in the preparation of the Company’s financial statements; accordingly, it is possible that the actual results could differ from these estimates and assumptions that could have a material effect on the reported amounts of the Company’s financial position and results of operations. Operating results for the nine-month period ended September 30, 2019 are not necessarily indicative of the results that may be expected for the year ending December 31, 2019. The condensed consolidated balance sheet at December 31, 2018 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by generally accepted accounting principles in the U.S. for complete financial statements.</div></div>

<div style="font: 10pt TIMES NEW ROMAN; text-align: justify;">As of September 30, 2019, the Company has cumulative losses totaling $68,0884,000 and negative working capital of $1,565,000. The Company incurred a net loss of $115,000 for the nine months ended September 30, 2019. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. Because of these conditions, the Company will require additional working capital to develop business operations. Management’s plans are to raise additional working capital through the continued licensing of its technology as well as to generate revenues for other services. There are no assurances that the Company will be able to achieve the level of revenues adequate to generate sufficient cash flow from operations to support the Company’s working capital requirements. To the extent that funds generated are insufficient, the Company will have to raise additional working capital. No assurance can be given that additional financing will be available, or if available, will be on terms acceptable to the Company. If adequate working capital is not available, the Company may not continue its operations. The financial statements do not include any adjustments relating to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</div>

<div style="font: 10pt TIMES NEW ROMAN; text-align: justify;">BASIS OF CONSOLIDATION: The consolidated financial statements include the accounts of Manhattan Scientific, Inc., its wholly owned subsidiary Metallicum. All significant intercompany balances and transactions have been eliminated. USE OF ESTIMATES: The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amount of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. A significant estimate includes the carrying value of the Companys patents, fair value of the Companys common stock, assumptions used in calculating the value of stock options, depreciation and amortization. CASH CONCENTRATION: The Companys cash accounts are federally insured up to $250,000 for each financial institution we hold our accounts in. As of September 30, 2019 and December 31, 2018, the cash balances did not exceed the federally insured limits. INTANGIBLE ASSETS: License Agreements In 2008, the Company obtained licenses to the rights of certain patents regarding nanostructured materials developed by another company as a result of the acquisition of Metallicum. The purchase price paid for these licenses was $305,000, which represented its fair value. The Company obtained an exclusive license on two patents and a non-exclusive license on the third patent. The value attributable to license agreements is being amortized over the period of its estimated benefit period of 10 years. At September 30, 2019 and December 31, 2018, the license agreements were fully amortized. Under the terms of the agreement, the Company may be required to pay royalties, as defined, to the licensors. In 2009, the Company entered into a patent license agreement with Los Alamos National Security LLC for the exclusive use of certain technology relating to the manufacture and application of nanostructuring metals and alloys. The purchase price paid for this license agreement was $33,000 based on the fair market value of 2,000,000 shares of common stock issued. The value attributable to license agreements is being amortized over the period of its estimated benefit period of 10 years. At September 30, 2019 and December 31, 2018, the license agreements were fully amortized. Beginning in 2010, the Company was required to pay an annual license fee of $10,000 and may be required to pay royalties, as defined, to the licensors. ASSETS HELD FOR SALE: Non-current assets are classified as held for sale if it is highly probably that they will be recovered primarily through sale rather than through continuing use. Immediately before classification as held for sale, the assets are remeasured at the lower of their carrying amount and fair value less costs to sell. Any impairment loss on initial classification as held for sale and subsequent gains and losses on re-measurement are recognized in profit or loss. Gains are not recognized in excess of any cumulative impairment loss. During the nine months ended September 30, 2019, the Company sold the assets held for sale that were presented on the balance sheet as of December 31, 2018. During the year ended December 31, 2018, the Company recorded impairment and adjusted the asset valuation to $1.2 million. The Company sold the assets for a total of $1.2 million of which $300,000 was received during the three-month period ended June 30, 2019. The remaining $900,000 will be collected during the next three years in equal increments on the anniversary date of the agreement. REVENUE RECOGNITION: The Company recognizes revenue in accordance with generally accepted accounting principles as outlined in the Financial Accounting Standard Boards (FASB) Accounting Standards Codification (ASC) 606, Revenue From Contracts with Customers, which consists of five steps to evaluating contracts with customers for revenue recognition: (i) identify the contract with the customer; (ii) identity the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price; and (v) recognize revenue when or as the entity satisfied a performance obligation. Revenue recognition occurs at the time we satisfy a performance obligation to our customers, when control transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. We only record revenue when collectability is probable. FAIR VALUE OF FINANCIAL INSTRUMENTS Effective January 1, 2008, the Company adopted FASB ASC 820, Fair Value Measurements and Disclosures, Pre Codification SFAS No. 157, Fair Value Measurements, which provides a framework for measuring fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The standard also expands disclosures about instruments measured at fair value and establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: Level 1 Quoted prices for identical assets and liabilities in active markets;Level 2 Quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets; andLevel 3 Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. The Company designates cash equivalents (consisting of money market funds) and investments in securities of publicly traded companies as Level 1. The total amount of the Companys investment classified as Level 3 is de minimis. Fair value of financial instruments: The carrying amounts of financial instruments, including cash and cash equivalents, short-term investments, accounts payable, accrued expenses and notes payables approximated fair value as of September 30, 2019 and December 31, 2018 because of the relative short term nature of these instruments.  During the year ended December 31, 2017, the Company elected fair value option for its investment in Imagion Biosystems, Inc. a Nevada company (Imagion) based on triggering event of dilution of ownership, which lead to the deconsolidation of Imagion. Investments in Imagion are measured at fair value as opposed to equity method based on ASC 825-10. The guidance allows entities to elect to measure certain financial assets and financial liabilities (as well as certain nonfinancial instruments that are similar to financial instruments) at fair value. Investments over which an investor has the ability to exercise significant influence are eligible for the fair value option as they represent recognized financial assets. When the fair value option is elected for an instrument, all subsequent changes in fair value for that instrument are reported in earnings.  As of September 30, 2019, the Company holds approximately 19% of the total issued and outstanding shares of Imagion and is reported under fair value method under ASC 320. Management determined that it was appropriate to carry its investment in Imagion at fair value because the investment is traded on the Australian stock exchange and has daily trading activity and is a better indicator of value. The investments are re-measured at the end of each quarter based on the trading price and converted from AUD to USD. Any change in the value is reported on the income statement as an unrealized gain or loss. INCOME TAXES The Company accounts for income taxes under an asset and liability approach. This process involves calculating the temporary and permanent differences between the carrying amounts of the assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The temporary differences result in deferred tax assets and liabilities, which would be recorded on the Companys consolidated balance sheets in accordance with ASC 740, which established financial accounting and reporting standards for the effect of income taxes. The Company must assess the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent the Company believes that recovery is not likely, the Company must establish a valuation allowance. Changes in the Companys valuation allowance in a period are recorded through the income tax provision on the consolidated statements of operations. ASC 740-10 clarifies the accounting for uncertainty in income taxes recognized in an entitys financial statements and prescribes a recognition threshold and measurement attributes for financial statement disclosure of tax positions taken or expected to be taken on a tax return. Under ASC 740-10, the impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Additionally, ASC 740-10 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. As a result of the implementation of ASC 740-10, the Company recognized no material adjustment in the liability for unrecognized income tax benefits. BASIC AND DILUTED LOSS PER SHARE In accordance with FASB ASC 260, Earnings Per Share, the basic loss per share is computed by dividing the loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Basic net loss per share excludes the dilutive effect of stock options or warrants and convertible notes. Diluted net earnings (loss) per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents, consisting of shares that might be issued upon exercise of common stock options and warrants. In periods where losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. As of September 30, 2019 and 2018, 40,105,000 and 50,798,182, respectively, dilutive shares were excluded from the calculation of diluted loss per common share for the nine months ended but were included for the diluted earnings per share calculation for the three months ended. LEASES The Company leases a facility with terms of month to month for its headquarters and had a lease on a facility through April 2021. The lease may be cancelled at any time with three months written notice before April 2020 and 2021, the anniversary dates of the lease. The Company adopted ASC 842 on January 1, 2019 and has evaluated and has no impact on the financial statements as under the practical expedient the leases consist of terms less then one year, and therefore is not required to capitalize the lease.  During June 2019, the Company entered into an assignment and assumption of lease with the landlord and another entity for the lease term through April 2021. RECENT ACCOUNTING PRONOUNCEMENTS The Company does not expect the adoption of recently issued accounting pronouncements to have a potential impact on the Companys results of operations, financial position or cash flow. Leases:  In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) and subsequent amendments to the initial guidance: ASU 2017-13, ASU 2018-10, ASU 2018-11, ASU 2018-20 and ASU 2019-01 (collectively, Topic 842). Topic 842 requires companies to generally recognize on the balance sheet operating and financing lease liabilities and corresponding right-of-use assets. The Company early adopted Topic ASC 842 using the effective date of January 1, 2019 as the date of our initial application of the standard. The Company used the new transition election to not restate comparative periods and elected the package of practical expedients upon adoption, which permits the Company to not reassess under the new standard the Companys prior conclusions about lease identification, lease classification and initial direct costs. Consequently, financial information for the comparative periods will not be updated. Upon adoption, there was no material impact to the financial statements. Stock Based Compensation: In June 2018, FASB issued ASU No. 2018-07, Compensation Stock Compensation (Topic 718),Improvements to Nonemployee Share Based Payment Accounting. The amendments in this Update expand the scope of stock compensation to include share-based payment transactions for acquiring goods and services from nonemployees. The guidance in this Update does not apply to transactions involving equity instruments granted to a lender or investor that provides financing to the issuer. The guidance is effective for fiscal years beginning after December 31, 2018 including interim periods within the fiscal year. The Company adopted with an effective date of January 1, 2019. Upon adoption, there was no material impact to the financial statements.  There are no other recent accounting pronouncements that are expected to have a material impact on the condensed consolidated financial statements. </div>

<div style="font: 10pt TIMES NEW ROMAN; text-align: justify;">As of September 30, 2019, the Company owns 63,999,476 shares of Imagion Biosystems (Imagion), resulting in a noncontrolling interest of Imagions issued and outstanding common stock. Initially, the Company held approximately 31% of Imagions total issued and outstanding common stock and was later was decreased to approximately 19%. Based upon Imagions trading price on September 30, 2019, approximately $0.033 per share, the fair value of the Imagion shares was approximately $2,114,000. During the nine months ended September 30, 2019, the Company recorded an unrealized gain in its investment of $764,000. During the nine months ended September 30, 2019, the Company sold 100,000 shares of Imagion and received cash proceeds of $2,480.</div>

<div style="font: 10pt TIMES NEW ROMAN; text-align: justify;">On March 11, 2019, the Company received a loan for $50,000 and entered into a promissory note and security agreement with a third party. The loan was secured with ECAP-C machines. The due date of the loan was the earlier of April 30, 2019 or the closing of the transaction with the third party. Interest shall accrue at a rate of 6% per annum from April 11, 2019 until paid in full. On May 1, 2019, the transaction closed and agreements were executed. The Company repaid the $50,000 upon closing of the transaction. </div>

<div style="font: 10pt TIMES NEW ROMAN; text-align: justify;">On May 1, 2019, the Company, entered into an agreement with a non-affiliated third party (“Third Party”), providing for an exclusive license by the Company of its ECAP technology to the Third Party for a term of 17 years unless terminated sooner, a sublicense by the Company to the Third Party of its rights under that certain Exclusive Field-of-Use Patent License Agreement dated January 5, 2009 entered with The Los Alamos National Laboratory for a term until the expiration of the last valid claim to expire of the patents pursuant to such agreement and the sale by the Company of ECAP-C machines to the Third party.  As part of the above license agreements, the Company will receive royalty payments, including minimum payments, based on a percentage of the Third Party’s sales. Royalties will be 10% on gross sales of licensed dental products and average of 5% on all other sales of licensed products. During the nine months ended September 30, 2019, the Company received $50,000 as a minimum royalty payment. </div> <div style="font: 10pt TIMES NEW ROMAN; text-align: justify;">During the nine months ended September 30, 2019, the Company recorded revenue of $22,000 for which the services were performed and completed in 2018, but the Company performed an assessment and determined the collectability was not reasonably assured and did not record as revenue in 2018 per ASC 605. The original contract was dated in 2017. In 2019, the Company collected on the invoice and recorded revenue upon receipt of the funds.</div>

<div style="font: 10pt TIMES NEW ROMAN; text-align: justify;">As of September 30, 2019, we did not have any known commitments or contingencies. Legal matter contingenciesThe Company believes, based on current knowledge and after consultation with counsel, that it is not currently party to any material pending proceedings, individually or in the aggregate, the resolution of which would have a material effect on the Company.  Provisions for losses are established in accordance with ASC 450, “Contingencies” when warranted.  Once established, such provisions are adjusted when there is more information available of when an event occurs requiring a change.</div>

<div style="font: 10pt TIMES NEW ROMAN; text-align: justify;">During the three months ended June 30, 2019, the Company issued 24,000,000 shares of common stock to its board of directors for services valued at $360,000. The shares were valued based on the market price of the Company’s common shares of $0.015 on the grant date. During the three months ended June 30, 2019, the Company issued 500,000 options to its advisors for services valued at approximately $7,000. The options are exercisable at $0.015 and have a life of 5 years. </div>

<div style="font: 10pt TIMES NEW ROMAN; text-align: justify;">In accordance with ASC 855-10, the Company has analyzed its operations subsequent to September 30, 2019 to the date these financial statements were issued, and there were no material subsequent events to disclose in these financial statements.  </div>

<div style="font: 10pt TIMES NEW ROMAN; text-align: justify;">The consolidated financial statements include the accounts of Manhattan Scientific, Inc., its wholly owned subsidiary Metallicum. All significant intercompany balances and transactions have been eliminated.</div>

<div style="font: 10pt TIMES NEW ROMAN; text-align: justify;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amount of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. A significant estimate includes the carrying value of the Company’s patents, fair value of the Company’s common stock, assumptions used in calculating the value of stock options, depreciation and amortization.</div>

<div style="font: 10pt TIMES NEW ROMAN; text-align: justify;">The Companys cash accounts are federally insured up to $250,000 for each financial institution we hold our accounts in. As of September 30, 2019 and December 31, 2018, the cash balances did not exceed the federally insured limits.</div>

<div style="font: 10pt TIMES NEW ROMAN; text-align: justify;">License Agreements In 2008, the Company obtained licenses to the rights of certain patents regarding nanostructured materials developed by another company as a result of the acquisition of Metallicum. The purchase price paid for these licenses was $305,000, which represented its fair value. The Company obtained an exclusive license on two patents and a non-exclusive license on the third patent. The value attributable to license agreements is being amortized over the period of its estimated benefit period of 10 years. At September 30, 2019 and December 31, 2018, the license agreements were fully amortized. Under the terms of the agreement, the Company may be required to pay royalties, as defined, to the licensors. In 2009, the Company entered into a patent license agreement with Los Alamos National Security LLC for the exclusive use of certain technology relating to the manufacture and application of nanostructuring metals and alloys. The purchase price paid for this license agreement was $33,000 based on the fair market value of 2,000,000 shares of common stock issued. The value attributable to license agreements is being amortized over the period of its estimated benefit period of 10 years. At September 30, 2019 and December 31, 2018, the license agreements were fully amortized. Beginning in 2010, the Company was required to pay an annual license fee of $10,000 and may be required to pay royalties, as defined, to the licensors.</div>

<div style="font: 10pt TIMES NEW ROMAN; text-align: justify;">Non-current assets are classified as held for sale if it is highly probably that they will be recovered primarily through sale rather than through continuing use. Immediately before classification as held for sale, the assets are remeasured at the lower of their carrying amount and fair value less costs to sell. Any impairment loss on initial classification as held for sale and subsequent gains and losses on re-measurement are recognized in profit or loss. Gains are not recognized in excess of any cumulative impairment loss. During the nine months ended September 30, 2019, the Company sold the assets held for sale that were presented on the balance sheet as of December 31, 2018. During the year ended December 31, 2018, the Company recorded impairment and adjusted the asset valuation to $1.2 million. The Company sold the assets for a total of $1.2 million of which $300,000 was received during the three-month period ended June 30, 2019. The remaining $900,000 will be collected during the next three years in equal increments on the anniversary date of the agreement. </div>

<div style="font: 10pt TIMES NEW ROMAN; text-align: justify;">The Company recognizes revenue in accordance with generally accepted accounting principles as outlined in the Financial Accounting Standard Boards (FASB) Accounting Standards Codification (ASC) 606, Revenue From Contracts with Customers, which consists of five steps to evaluating contracts with customers for revenue recognition: (i) identify the contract with the customer; (ii) identity the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price; and (v) recognize revenue when or as the entity satisfied a performance obligation. Revenue recognition occurs at the time we satisfy a performance obligation to our customers, when control transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. We only record revenue when collectability is probable.</div>

<div style="font: 10pt TIMES NEW ROMAN; text-align: justify;">Effective January 1, 2008, the Company adopted FASB ASC 820, Fair Value Measurements and Disclosures, Pre Codification SFAS No. 157, “Fair Value Measurements”, which provides a framework for measuring fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The standard also expands disclosures about instruments measured at fair value and establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: Level 1 — Quoted prices for identical assets and liabilities in active markets;Level 2 — Quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets; andLevel 3 — Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. The Company designates cash equivalents (consisting of money market funds) and investments in securities of publicly traded companies as Level 1. The total amount of the Company’s investment classified as Level 3 is de minimis. Fair value of financial instruments: The carrying amounts of financial instruments, including cash and cash equivalents, short-term investments, accounts payable, accrued expenses and notes payables approximated fair value as of September 30, 2019 and December 31, 2018 because of the relative short term nature of these instruments.  During the year ended December 31, 2017, the Company elected fair value option for its investment in Imagion Biosystems, Inc. a Nevada company (“Imagion”) based on triggering event of dilution of ownership, which lead to the deconsolidation of Imagion. Investments in Imagion are measured at fair value as opposed to equity method based on ASC 825-10. The guidance allows entities to elect to measure certain financial assets and financial liabilities (as well as certain nonfinancial instruments that are similar to financial instruments) at fair value. Investments over which an investor has the ability to exercise significant influence are eligible for the fair value option as they represent recognized financial assets. When the fair value option is elected for an instrument, all subsequent changes in fair value for that instrument are reported in earnings.  As of September 30, 2019, the Company holds approximately 19% of the total issued and outstanding shares of Imagion and is reported under fair value method under ASC 320. Management determined that it was appropriate to carry its investment in Imagion at fair value because the investment is traded on the Australian stock exchange and has daily trading activity and is a better indicator of value. The investments are re-measured at the end of each quarter based on the trading price and converted from AUD to USD. Any change in the value is reported on the income statement as an unrealized gain or loss. </div>

<div style="font: 10pt TIMES NEW ROMAN; text-align: justify;">The Company accounts for income taxes under an asset and liability approach. This process involves calculating the temporary and permanent differences between the carrying amounts of the assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The temporary differences result in deferred tax assets and liabilities, which would be recorded on the Company’s consolidated balance sheets in accordance with ASC 740, which established financial accounting and reporting standards for the effect of income taxes. The Company must assess the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent the Company believes that recovery is not likely, the Company must establish a valuation allowance. Changes in the Company’s valuation allowance in a period are recorded through the income tax provision on the consolidated statements of operations. ASC 740-10 clarifies the accounting for uncertainty in income taxes recognized in an entity’s financial statements and prescribes a recognition threshold and measurement attributes for financial statement disclosure of tax positions taken or expected to be taken on a tax return. Under ASC 740-10, the impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Additionally, ASC 740-10 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. As a result of the implementation of ASC 740-10, the Company recognized no material adjustment in the liability for unrecognized income tax benefits. </div>

<div style="font: 10pt TIMES NEW ROMAN; text-align: justify;">In accordance with FASB ASC 260, “Earnings Per Share,” the basic loss per share is computed by dividing the loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Basic net loss per share excludes the dilutive effect of stock options or warrants and convertible notes. Diluted net earnings (loss) per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents, consisting of shares that might be issued upon exercise of common stock options and warrants. In periods where losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. As of September 30, 2019 and 2018, 40,105,000 and 50,798,182, respectively, dilutive shares were excluded from the calculation of diluted loss per common share for the nine months ended but were included for the diluted earnings per share calculation for the three months ended.</div>

<div style="font: 10pt TIMES NEW ROMAN; text-align: justify;">The Company leases a facility with terms of month to month for its headquarters and had a lease on a facility through April 2021. The lease may be cancelled at any time with three months written notice before April 2020 and 2021, the anniversary dates of the lease. The Company adopted ASC 842 on January 1, 2019 and has evaluated and has no impact on the financial statements as under the practical expedient the leases consist of terms less then one year, and therefore is not required to capitalize the lease.  During June 2019, the Company entered into an assignment and assumption of lease with the landlord and another entity for the lease term through April 2021. </div>

<div style="font: 10pt TIMES NEW ROMAN; text-align: justify;">The Company does not expect the adoption of recently issued accounting pronouncements to have a potential impact on the Company’s results of operations, financial position or cash flow. Leases:  In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) and subsequent amendments to the initial guidance: ASU 2017-13, ASU 2018-10, ASU 2018-11, ASU 2018-20 and ASU 2019-01 (collectively, Topic 842). Topic 842 requires companies to generally recognize on the balance sheet operating and financing lease liabilities and corresponding right-of-use assets. The Company early adopted Topic ASC 842 using the effective date of January 1, 2019 as the date of our initial application of the standard. The Company used the new transition election to not restate comparative periods and elected the package of practical expedients upon adoption, which permits the Company to not reassess under the new standard the Company’s prior conclusions about lease identification, lease classification and initial direct costs. Consequently, financial information for the comparative periods will not be updated. Upon adoption, there was no material impact to the financial statements. Stock Based Compensation: In June 2018, FASB issued ASU No. 2018-07, Compensation – Stock Compensation (Topic 718),Improvements to Nonemployee Share Based Payment Accounting. The amendments in this Update expand the scope of stock compensation to include share-based payment transactions for acquiring goods and services from nonemployees. The guidance in this Update does not apply to transactions involving equity instruments granted to a lender or investor that provides financing to the issuer. The guidance is effective for fiscal years beginning after December 31, 2018 including interim periods within the fiscal year. The Company adopted with an effective date of January 1, 2019. Upon adoption, there was no material impact to the financial statements.  There are no other recent accounting pronouncements that are expected to have a material impact on the condensed consolidated financial statements. </div>

-1565000

250000

2000000

50798182

40105000

P10Y

300000

1200000

The remaining $900,000 will be collected during the next three years in equal increments on the anniversary date of the agreement.

305000

33000

Purchase price paid for this license agreement was $33,000 based on the fair market value of 2,000,000 shares of common stock issued 10000 63999476 2114000 0.31 0.19 0.033

100000

2480

764000

50000 0.06

50000

0.1 0.05

24000000

0.015

360000

0.015 500000 7000

P5Y

EX-101.SCH 5 mhtx-20190930.xsd XBRL TAXONOMY EXTENSION SCHEMA 0000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (unaudited) link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) link:presentationLink link:calculationLink link:definitionLink 0000007 - Disclosure - BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - GOING CONCERN link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS link:presentationLink link:calculationLink link:definitionLink 000010 - Disclosure - INVESTMENT IN IMAGION BIOSYSTEMS link:presentationLink link:calculationLink link:definitionLink 000011 - Disclosure - NOTES PAYABLE link:presentationLink link:calculationLink link:definitionLink 000012 - Disclosure - LICENSE AGREEMENT link:presentationLink link:calculationLink link:definitionLink 000013 - Disclosure - REVENUE link:presentationLink link:calculationLink link:definitionLink 000014 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 000015 - Disclosure - STOCKHOLDERS EQUITY (DEFICIT) link:presentationLink link:calculationLink link:definitionLink 000016 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 000017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Policies) link:presentationLink link:calculationLink link:definitionLink 000018 - Disclosure - GOING CONCERN (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000020 - Disclosure - INVESTMENT IN IMAGION BIOSYSTEMS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000021 - Disclosure - NOTES PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000022 - Disclosure - LICENSE AGREEMENT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000023 - Disclosure - REVENUE (Detail Narrative) link:presentationLink link:calculationLink link:definitionLink 000024 - Disclosure - STOCKHOLDERS EQUITY (DEFICIT) (Detail Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 6 mhtx-20190930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Current Fiscal Year End Date Entity Small Business Entity Shell Company Entity Emerging Growth Company Entity Current Reporting Status Document Period End Date Entity Filer Category Document Fiscal Period Focus Document Fiscal Year Focus Entity Common Stock Shares Outstanding CONDENSED CONSOLIDATED BALANCE SHEETS Statement [Table] Statement [Line Items] Class of Stock [Axis] Series D convertible preferred Stock [Member] Class A Convertible Preferred Stock [Member] Class B Convertible Preferred Stock [Member] Class C Redeemable Convertible Preferred Stock [Member] Current assets: Cash Prepaid expenses Due from the sale of assets - current portion Total current assets [Assets, Current] Investment in equity securities Property and equipment, net Assets held for sale Due from the sale of assets held for sale Other assets Total assets [Assets] Current liabilities: Accounts payable and accrued expenses Accrued expenses - related parties Total current liabilities [Liabilities, Current] Long-term liabilities: Total long-term liabilities Total liabilities [Liabilities] Commitments and Contingencies - Note 8 STOCKHOLDERS' EQUITY (DEFICIT) Capital stock $.001 par value Preferred, authorized 447,804 shares, 0 and 0 shares issued, and outstanding, respectively Capital stock $.001 par value Common, authorized 950,000,000 shares, 557,781,064 and 533,781,064 shares issued, and outstanding, respectively Additional paid-in-capital Accumulated deficit Total stockholders' equity (deficit) TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' EQUITY (DEFICIT) [Liabilities and Equity] Series D convertible preferred mandatory redeemable, authorized 105,671 shares, 105,671 and 105,671 shares issued and outstanding, respectively Preferred stock, shares par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) Revenue Operating costs: Direct cost of revenue General and administrative expenses Research and development Asset impairment Total operating costs and expenses Loss from operations Other income and (expenses): Gain (loss) on fair value adjustment of investments Net loss before provision for income taxes Income tax expense NET INCOME (LOSS) BASIC AND DILUTED INCOME (LOSS) PER COMMON SHARE: Weighted average number of common shares outstanding (Basic) Basic income (loss) per common share Weighted average number of common shares outstanding (Diluted) Diluted income (loss) per common share CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (unaudited) Equity Components [Axis] Preferred Stock Series B [Member] Common Stock [Member] Additional Paid-in Capital [Member] Accumulated Deficit [Member] Balance, shares [Shares, Issued] Balance, amount Net Income (Loss) Options issued for services Common stock issued for services, shares Common stock issued for services, amount Balance, shares Balance, amount CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) CASH FLOWS FROM OPERATING ACTIVITIES Net loss Adjustments to reconcile net loss to net cash used in operating activities: Common stock issued for services Stock options issued/vested for services Depreciation and amortization Asset impairment Gain (loss) on fair value adjustment of investments [Assets, Fair Value Adjustment] Changes in: Prepaid expenses [Increase (Decrease) in Prepaid Expense] Accounts payable and accrued expenses [Increase (Decrease) in Accounts Payable and Accrued Liabilities] Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES: Purchase of fixed assets Proceeds from sale of assets held for sale Proceeds from sale of investments Net cash used in investing activities CASH FLOWS FROM FINANCING ACTIVITIES: Net cash provided by financing activities NET DECREASE IN CASH CASH, BEGINNING OF PERIOD CASH, END OF PERIOD SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Interest paid Income taxes paid BASIS OF PRESENTATION NOTE 1 - BASIS OF PRESENTATION GOING CONCERN NOTE - 2 GOING CONCERN SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS INVESTMENT IN IMAGION BIOSYSTEMS NOTE 4 - INVESTMENT IN IMAGION BIOSYSTEMS NOTES PAYABLE NOTE 5 - NOTES PAYABLE LICENSE AGREEMENT NOTE 6 - LICENSE AGREEMENT REVENUE NOTE 7 - REVENUE COMMITMENTS AND CONTINGENCIES NOTE 8 - COMMITMENTS AND CONTINGENCIES STOCKHOLDERS EQUITY (DEFICIT) NOTE 9 - STOCKHOLDERS EQUITY (DEFICIT) SUBSEQUENT EVENTS NOTE 10 - SUBSEQUENT EVENTS BASIS OF CONSOLIDATION USE OF ESTIMATES CASH CONCENTRATION INTANGIBLE ASSETS ASSETS HELD FOR SALE REVENUE RECOGNITION FAIR VALUE OF FINANCIAL INSTRUMENTS INCOME TAXES BASIC AND DILUTED LOSS PER SHARE LEASES RECENT ACCOUNTING PRONOUNCEMENTS Working capital deficit Cumulative losses Net income (loss) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details Narrative) Related Party Transactions By Related Party Axis Plan Name Axis Finite Lived Intangible Assets By Major Class Axis Los Alamos National Security LLC [Member] Patent license agreement [Member] Metallicum [Member] License agreements[Member] Cash FDIC insured amount Diluted shares excluded Amortization period of values acquisition Asset Imapairment Proceed from sale of asset Description assets held for sale Common stock, shares issued Purchase price of licences under agreement Purchase price of licenses under agreement Annual license fee INVESTMENT IN IMAGION BIOSYSTEMS (Details Narrative) Imagion Biosystems, Inc., [Member] sale of common stock shares Proceeds from sale of common stock shares Common stock acquired shares Fair value of Shares Noncontrolling interest rate Noncontrolling interest rate decreased Trading price per share Investment (Loss) on fair value adjustment of investments Short Term Debt Type Axis Security agreement [Member] Repayment of notes payable Interest rate Proceeds from note payable LICENSE AGREEMENT (Details Narrative) Minimum Royalty Payment Royalty percentage on dental products Royalty percentage on other licensed products Revenue Related Party Transaction [Axis] Director [Member] Option exercisable price Share issued Option Services EX-101.CAL 7 mhtx-20190930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.PRE 8 mhtx-20190930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EX-101.DEF 9 mhtx-20190930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE XML 10 R21.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE (Details Narrative) - USD ($)	Apr. 11, 2019	Mar. 11, 2019	May 01, 2019
Repayment of notes payable			$ 50,000
Interest rate	6.00%
Security agreement [Member]
Proceeds from note payable		$ 50,000

XML 11 R4.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)
Revenue	$ 22,000		$ 72,000
Operating costs:
Direct cost of revenue				7,000
General and administrative expenses	187,000	322,000	945,000	1,089,000
Research and development	3,000		6,000	52,000
Asset impairment				842,000
Total operating costs and expenses	190,000	322,000	951,000	1,990,000
Loss from operations	(168,000)	(322,000)	(879,000)	(1,990,000)
Other income and (expenses):
Gain (loss) on fair value adjustment of investments	1,397,000	646,000	764,000	(2,727,000)
Net loss before provision for income taxes
Income tax expense
NET INCOME (LOSS)	$ 1,229,000	$ 324,000	$ (115,000)	$ (4,717,000)
BASIC AND DILUTED INCOME (LOSS) PER COMMON SHARE:
Weighted average number of common shares outstanding (Basic)	557,781,064	533,781,064	546,528,317	533,781,064
Basic income (loss) per common share	$ 0.00	$ 0.00	$ (0.00)	$ (0.01)
Weighted average number of common shares outstanding (Diluted)	597,886,064	584,579,246	546,528,317	533,781,064
Diluted income (loss) per common share	$ 0.00	$ 0.00	$ (0.00)	$ (0.01)

XML 12 R17.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Policies)	9 Months Ended
	Sep. 30, 2019
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS
BASIS OF CONSOLIDATION	The consolidated financial statements include the accounts of Manhattan Scientific, Inc., its wholly owned subsidiary Metallicum. All significant intercompany balances and transactions have been eliminated.
USE OF ESTIMATES	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amount of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. A significant estimate includes the carrying value of the Company’s patents, fair value of the Company’s common stock, assumptions used in calculating the value of stock options, depreciation and amortization.
CASH CONCENTRATION	The Companys cash accounts are federally insured up to $250,000 for each financial institution we hold our accounts in. As of September 30, 2019 and December 31, 2018, the cash balances did not exceed the federally insured limits.
INTANGIBLE ASSETS	License Agreements In 2008, the Company obtained licenses to the rights of certain patents regarding nanostructured materials developed by another company as a result of the acquisition of Metallicum. The purchase price paid for these licenses was $305,000, which represented its fair value. The Company obtained an exclusive license on two patents and a non-exclusive license on the third patent. The value attributable to license agreements is being amortized over the period of its estimated benefit period of 10 years. At September 30, 2019 and December 31, 2018, the license agreements were fully amortized. Under the terms of the agreement, the Company may be required to pay royalties, as defined, to the licensors. In 2009, the Company entered into a patent license agreement with Los Alamos National Security LLC for the exclusive use of certain technology relating to the manufacture and application of nanostructuring metals and alloys. The purchase price paid for this license agreement was $33,000 based on the fair market value of 2,000,000 shares of common stock issued. The value attributable to license agreements is being amortized over the period of its estimated benefit period of 10 years. At September 30, 2019 and December 31, 2018, the license agreements were fully amortized. Beginning in 2010, the Company was required to pay an annual license fee of $10,000 and may be required to pay royalties, as defined, to the licensors.
ASSETS HELD FOR SALE	Non-current assets are classified as held for sale if it is highly probably that they will be recovered primarily through sale rather than through continuing use. Immediately before classification as held for sale, the assets are remeasured at the lower of their carrying amount and fair value less costs to sell. Any impairment loss on initial classification as held for sale and subsequent gains and losses on re-measurement are recognized in profit or loss. Gains are not recognized in excess of any cumulative impairment loss. During the nine months ended September 30, 2019, the Company sold the assets held for sale that were presented on the balance sheet as of December 31, 2018. During the year ended December 31, 2018, the Company recorded impairment and adjusted the asset valuation to $1.2 million. The Company sold the assets for a total of $1.2 million of which $300,000 was received during the three-month period ended June 30, 2019. The remaining $900,000 will be collected during the next three years in equal increments on the anniversary date of the agreement.
REVENUE RECOGNITION	The Company recognizes revenue in accordance with generally accepted accounting principles as outlined in the Financial Accounting Standard Boards (FASB) Accounting Standards Codification (ASC) 606, Revenue From Contracts with Customers, which consists of five steps to evaluating contracts with customers for revenue recognition: (i) identify the contract with the customer; (ii) identity the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price; and (v) recognize revenue when or as the entity satisfied a performance obligation. Revenue recognition occurs at the time we satisfy a performance obligation to our customers, when control transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. We only record revenue when collectability is probable.
FAIR VALUE OF FINANCIAL INSTRUMENTS	Effective January 1, 2008, the Company adopted FASB ASC 820, Fair Value Measurements and Disclosures, Pre Codification SFAS No. 157, “Fair Value Measurements”, which provides a framework for measuring fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The standard also expands disclosures about instruments measured at fair value and establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: Level 1 — Quoted prices for identical assets and liabilities in active markets; Level 2 — Quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets; and Level 3 — Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. The Company designates cash equivalents (consisting of money market funds) and investments in securities of publicly traded companies as Level 1. The total amount of the Company’s investment classified as Level 3 is de minimis. Fair value of financial instruments: The carrying amounts of financial instruments, including cash and cash equivalents, short-term investments, accounts payable, accrued expenses and notes payables approximated fair value as of September 30, 2019 and December 31, 2018 because of the relative short term nature of these instruments. During the year ended December 31, 2017, the Company elected fair value option for its investment in Imagion Biosystems, Inc. a Nevada company (“Imagion”) based on triggering event of dilution of ownership, which lead to the deconsolidation of Imagion. Investments in Imagion are measured at fair value as opposed to equity method based on ASC 825-10. The guidance allows entities to elect to measure certain financial assets and financial liabilities (as well as certain nonfinancial instruments that are similar to financial instruments) at fair value. Investments over which an investor has the ability to exercise significant influence are eligible for the fair value option as they represent recognized financial assets. When the fair value option is elected for an instrument, all subsequent changes in fair value for that instrument are reported in earnings. As of September 30, 2019, the Company holds approximately 19% of the total issued and outstanding shares of Imagion and is reported under fair value method under ASC 320. Management determined that it was appropriate to carry its investment in Imagion at fair value because the investment is traded on the Australian stock exchange and has daily trading activity and is a better indicator of value. The investments are re-measured at the end of each quarter based on the trading price and converted from AUD to USD. Any change in the value is reported on the income statement as an unrealized gain or loss.
INCOME TAXES	The Company accounts for income taxes under an asset and liability approach. This process involves calculating the temporary and permanent differences between the carrying amounts of the assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The temporary differences result in deferred tax assets and liabilities, which would be recorded on the Company’s consolidated balance sheets in accordance with ASC 740, which established financial accounting and reporting standards for the effect of income taxes. The Company must assess the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent the Company believes that recovery is not likely, the Company must establish a valuation allowance. Changes in the Company’s valuation allowance in a period are recorded through the income tax provision on the consolidated statements of operations. ASC 740-10 clarifies the accounting for uncertainty in income taxes recognized in an entity’s financial statements and prescribes a recognition threshold and measurement attributes for financial statement disclosure of tax positions taken or expected to be taken on a tax return. Under ASC 740-10, the impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Additionally, ASC 740-10 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. As a result of the implementation of ASC 740-10, the Company recognized no material adjustment in the liability for unrecognized income tax benefits.
BASIC AND DILUTED LOSS PER SHARE	In accordance with FASB ASC 260, “Earnings Per Share,” the basic loss per share is computed by dividing the loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Basic net loss per share excludes the dilutive effect of stock options or warrants and convertible notes. Diluted net earnings (loss) per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents, consisting of shares that might be issued upon exercise of common stock options and warrants. In periods where losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. As of September 30, 2019 and 2018, 40,105,000 and 50,798,182, respectively, dilutive shares were excluded from the calculation of diluted loss per common share for the nine months ended but were included for the diluted earnings per share calculation for the three months ended.
LEASES	The Company leases a facility with terms of month to month for its headquarters and had a lease on a facility through April 2021. The lease may be cancelled at any time with three months written notice before April 2020 and 2021, the anniversary dates of the lease. The Company adopted ASC 842 on January 1, 2019 and has evaluated and has no impact on the financial statements as under the practical expedient the leases consist of terms less then one year, and therefore is not required to capitalize the lease. During June 2019, the Company entered into an assignment and assumption of lease with the landlord and another entity for the lease term through April 2021.
RECENT ACCOUNTING PRONOUNCEMENTS	The Company does not expect the adoption of recently issued accounting pronouncements to have a potential impact on the Company’s results of operations, financial position or cash flow. *Leases:* In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) and subsequent amendments to the initial guidance: ASU 2017-13, ASU 2018-10, ASU 2018-11, ASU 2018-20 and ASU 2019-01 (collectively, Topic 842). Topic 842 requires companies to generally recognize on the balance sheet operating and financing lease liabilities and corresponding right-of-use assets. The Company early adopted Topic ASC 842 using the effective date of January 1, 2019 as the date of our initial application of the standard. The Company used the new transition election to not restate comparative periods and elected the package of practical expedients upon adoption, which permits the Company to not reassess under the new standard the Company’s prior conclusions about lease identification, lease classification and initial direct costs. Consequently, financial information for the comparative periods will not be updated. Upon adoption, there was no material impact to the financial statements. Stock Based Compensation: In June 2018, FASB issued ASU No. 2018-07, Compensation – Stock Compensation (Topic 718),Improvements to Nonemployee Share Based Payment Accounting. The amendments in this Update expand the scope of stock compensation to include share-based payment transactions for acquiring goods and services from nonemployees. The guidance in this Update does not apply to transactions involving equity instruments granted to a lender or investor that provides financing to the issuer. The guidance is effective for fiscal years beginning after December 31, 2018 including interim periods within the fiscal year. The Company adopted with an effective date of January 1, 2019. Upon adoption, there was no material impact to the financial statements. There are no other recent accounting pronouncements that are expected to have a material impact on the condensed consolidated financial statements.

XML 13 R8.htm IDEA: XBRL DOCUMENT

GOING CONCERN	9 Months Ended
GOING CONCERN	Sep. 30, 2019
GOING CONCERN
NOTE - 2 GOING CONCERN	As of September 30, 2019, the Company has cumulative losses totaling $68,0884,000 and negative working capital of $1,565,000. The Company incurred a net loss of $115,000 for the nine months ended September 30, 2019. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. Because of these conditions, the Company will require additional working capital to develop business operations. Management’s plans are to raise additional working capital through the continued licensing of its technology as well as to generate revenues for other services. There are no assurances that the Company will be able to achieve the level of revenues adequate to generate sufficient cash flow from operations to support the Company’s working capital requirements. To the extent that funds generated are insufficient, the Company will have to raise additional working capital. No assurance can be given that additional financing will be available, or if available, will be on terms acceptable to the Company. If adequate working capital is not available, the Company may not continue its operations. The financial statements do not include any adjustments relating to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

XML 14 R13.htm IDEA: XBRL DOCUMENT

REVENUE	9 Months Ended
REVENUE	Sep. 30, 2019
REVENUE
NOTE 7 - REVENUE	During the nine months ended September 30, 2019, the Company recorded revenue of $22,000 for which the services were performed and completed in 2018, but the Company performed an assessment and determined the collectability was not reasonably assured and did not record as revenue in 2018 per ASC 605. The original contract was dated in 2017. In 2019, the Company collected on the invoice and recorded revenue upon receipt of the funds.

XML 16 R16.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS	9 Months Ended
SUBSEQUENT EVENTS	Sep. 30, 2019
SUBSEQUENT EVENTS
NOTE 10 - SUBSEQUENT EVENTS	In accordance with ASC 855-10, the Company has analyzed its operations subsequent to September 30, 2019 to the date these financial statements were issued, and there were no material subsequent events to disclose in these financial statements.

XML 17 R9.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS	9 Months Ended
	Sep. 30, 2019
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS
NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS	BASIS OF CONSOLIDATION: The consolidated financial statements include the accounts of Manhattan Scientific, Inc., its wholly owned subsidiary Metallicum. All significant intercompany balances and transactions have been eliminated. USE OF ESTIMATES: The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amount of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. A significant estimate includes the carrying value of the Companys patents, fair value of the Companys common stock, assumptions used in calculating the value of stock options, depreciation and amortization. CASH CONCENTRATION: The Companys cash accounts are federally insured up to $250,000 for each financial institution we hold our accounts in. As of September 30, 2019 and December 31, 2018, the cash balances did not exceed the federally insured limits. INTANGIBLE ASSETS: License Agreements In 2008, the Company obtained licenses to the rights of certain patents regarding nanostructured materials developed by another company as a result of the acquisition of Metallicum. The purchase price paid for these licenses was $305,000, which represented its fair value. The Company obtained an exclusive license on two patents and a non-exclusive license on the third patent. The value attributable to license agreements is being amortized over the period of its estimated benefit period of 10 years. At September 30, 2019 and December 31, 2018, the license agreements were fully amortized. Under the terms of the agreement, the Company may be required to pay royalties, as defined, to the licensors. In 2009, the Company entered into a patent license agreement with Los Alamos National Security LLC for the exclusive use of certain technology relating to the manufacture and application of nanostructuring metals and alloys. The purchase price paid for this license agreement was $33,000 based on the fair market value of 2,000,000 shares of common stock issued. The value attributable to license agreements is being amortized over the period of its estimated benefit period of 10 years. At September 30, 2019 and December 31, 2018, the license agreements were fully amortized. Beginning in 2010, the Company was required to pay an annual license fee of $10,000 and may be required to pay royalties, as defined, to the licensors. ASSETS HELD FOR SALE: Non-current assets are classified as held for sale if it is highly probably that they will be recovered primarily through sale rather than through continuing use. Immediately before classification as held for sale, the assets are remeasured at the lower of their carrying amount and fair value less costs to sell. Any impairment loss on initial classification as held for sale and subsequent gains and losses on re-measurement are recognized in profit or loss. Gains are not recognized in excess of any cumulative impairment loss. During the nine months ended September 30, 2019, the Company sold the assets held for sale that were presented on the balance sheet as of December 31, 2018. During the year ended December 31, 2018, the Company recorded impairment and adjusted the asset valuation to $1.2 million. The Company sold the assets for a total of $1.2 million of which $300,000 was received during the three-month period ended June 30, 2019. The remaining $900,000 will be collected during the next three years in equal increments on the anniversary date of the agreement. REVENUE RECOGNITION: The Company recognizes revenue in accordance with generally accepted accounting principles as outlined in the Financial Accounting Standard Boards (FASB) Accounting Standards Codification (ASC) 606, Revenue From Contracts with Customers, which consists of five steps to evaluating contracts with customers for revenue recognition: (i) identify the contract with the customer; (ii) identity the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price; and (v) recognize revenue when or as the entity satisfied a performance obligation. Revenue recognition occurs at the time we satisfy a performance obligation to our customers, when control transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. We only record revenue when collectability is probable. FAIR VALUE OF FINANCIAL INSTRUMENTS Effective January 1, 2008, the Company adopted FASB ASC 820, Fair Value Measurements and Disclosures, Pre Codification SFAS No. 157, Fair Value Measurements, which provides a framework for measuring fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The standard also expands disclosures about instruments measured at fair value and establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: Level 1 Quoted prices for identical assets and liabilities in active markets; Level 2 Quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets; and Level 3 Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. The Company designates cash equivalents (consisting of money market funds) and investments in securities of publicly traded companies as Level 1. The total amount of the Companys investment classified as Level 3 is de minimis. Fair value of financial instruments: The carrying amounts of financial instruments, including cash and cash equivalents, short-term investments, accounts payable, accrued expenses and notes payables approximated fair value as of September 30, 2019 and December 31, 2018 because of the relative short term nature of these instruments. During the year ended December 31, 2017, the Company elected fair value option for its investment in Imagion Biosystems, Inc. a Nevada company (Imagion) based on triggering event of dilution of ownership, which lead to the deconsolidation of Imagion. Investments in Imagion are measured at fair value as opposed to equity method based on ASC 825-10. The guidance allows entities to elect to measure certain financial assets and financial liabilities (as well as certain nonfinancial instruments that are similar to financial instruments) at fair value. Investments over which an investor has the ability to exercise significant influence are eligible for the fair value option as they represent recognized financial assets. When the fair value option is elected for an instrument, all subsequent changes in fair value for that instrument are reported in earnings. As of September 30, 2019, the Company holds approximately 19% of the total issued and outstanding shares of Imagion and is reported under fair value method under ASC 320. Management determined that it was appropriate to carry its investment in Imagion at fair value because the investment is traded on the Australian stock exchange and has daily trading activity and is a better indicator of value. The investments are re-measured at the end of each quarter based on the trading price and converted from AUD to USD. Any change in the value is reported on the income statement as an unrealized gain or loss. INCOME TAXES The Company accounts for income taxes under an asset and liability approach. This process involves calculating the temporary and permanent differences between the carrying amounts of the assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The temporary differences result in deferred tax assets and liabilities, which would be recorded on the Companys consolidated balance sheets in accordance with ASC 740, which established financial accounting and reporting standards for the effect of income taxes. The Company must assess the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent the Company believes that recovery is not likely, the Company must establish a valuation allowance. Changes in the Companys valuation allowance in a period are recorded through the income tax provision on the consolidated statements of operations. ASC 740-10 clarifies the accounting for uncertainty in income taxes recognized in an entitys financial statements and prescribes a recognition threshold and measurement attributes for financial statement disclosure of tax positions taken or expected to be taken on a tax return. Under ASC 740-10, the impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Additionally, ASC 740-10 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. As a result of the implementation of ASC 740-10, the Company recognized no material adjustment in the liability for unrecognized income tax benefits. BASIC AND DILUTED LOSS PER SHARE In accordance with FASB ASC 260, Earnings Per Share, the basic loss per share is computed by dividing the loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Basic net loss per share excludes the dilutive effect of stock options or warrants and convertible notes. Diluted net earnings (loss) per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents, consisting of shares that might be issued upon exercise of common stock options and warrants. In periods where losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. As of September 30, 2019 and 2018, 40,105,000 and 50,798,182, respectively, dilutive shares were excluded from the calculation of diluted loss per common share for the nine months ended but were included for the diluted earnings per share calculation for the three months ended. LEASES The Company leases a facility with terms of month to month for its headquarters and had a lease on a facility through April 2021. The lease may be cancelled at any time with three months written notice before April 2020 and 2021, the anniversary dates of the lease. The Company adopted ASC 842 on January 1, 2019 and has evaluated and has no impact on the financial statements as under the practical expedient the leases consist of terms less then one year, and therefore is not required to capitalize the lease. During June 2019, the Company entered into an assignment and assumption of lease with the landlord and another entity for the lease term through April 2021. RECENT ACCOUNTING PRONOUNCEMENTS The Company does not expect the adoption of recently issued accounting pronouncements to have a potential impact on the Companys results of operations, financial position or cash flow. *Leases:* In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) and subsequent amendments to the initial guidance: ASU 2017-13, ASU 2018-10, ASU 2018-11, ASU 2018-20 and ASU 2019-01 (collectively, Topic 842). Topic 842 requires companies to generally recognize on the balance sheet operating and financing lease liabilities and corresponding right-of-use assets. The Company early adopted Topic ASC 842 using the effective date of January 1, 2019 as the date of our initial application of the standard. The Company used the new transition election to not restate comparative periods and elected the package of practical expedients upon adoption, which permits the Company to not reassess under the new standard the Companys prior conclusions about lease identification, lease classification and initial direct costs. Consequently, financial information for the comparative periods will not be updated. Upon adoption, there was no material impact to the financial statements. Stock Based Compensation: In June 2018, FASB issued ASU No. 2018-07, Compensation Stock Compensation (Topic 718),Improvements to Nonemployee Share Based Payment Accounting. The amendments in this Update expand the scope of stock compensation to include share-based payment transactions for acquiring goods and services from nonemployees. The guidance in this Update does not apply to transactions involving equity instruments granted to a lender or investor that provides financing to the issuer. The guidance is effective for fiscal years beginning after December 31, 2018 including interim periods within the fiscal year. The Company adopted with an effective date of January 1, 2019. Upon adoption, there was no material impact to the financial statements. There are no other recent accounting pronouncements that are expected to have a material impact on the condensed consolidated financial statements.

XML 18 R12.htm IDEA: XBRL DOCUMENT

LICENSE AGREEMENT	9 Months Ended
LICENSE AGREEMENT	Sep. 30, 2019
LICENSE AGREEMENT
NOTE 6 - LICENSE AGREEMENT	On May 1, 2019, the Company, entered into an agreement with a non-affiliated third party (“Third Party”), providing for an exclusive license by the Company of its ECAP technology to the Third Party for a term of 17 years unless terminated sooner, a sublicense by the Company to the Third Party of its rights under that certain Exclusive Field-of-Use Patent License Agreement dated January 5, 2009 entered with The Los Alamos National Laboratory for a term until the expiration of the last valid claim to expire of the patents pursuant to such agreement and the sale by the Company of ECAP-C machines to the Third party. As part of the above license agreements, the Company will receive royalty payments, including minimum payments, based on a percentage of the Third Party’s sales. Royalties will be 10% on gross sales of licensed dental products and average of 5% on all other sales of licensed products. During the nine months ended September 30, 2019, the Company received $50,000 as a minimum royalty payment.

XML 19 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2019	Nov. 19, 2019
Document And Entity Information
Entity Registrant Name	MANHATTAN SCIENTIFICS INC
Entity Central Index Key	0001099132
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Document Period End Date	Sep. 30, 2019
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2019
Entity Common Stock Shares Outstanding		557,781,064

XML 20 R5.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (unaudited) - USD ($)	Total	Preferred Stock Series B [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
Balance, shares at Dec. 31, 2017		49,999	533,781,064
Balance, amount at Dec. 31, 2017	$ 8,161,000		$ 534,000	$ 67,289,000	$ (59,662,000)
Net Income (Loss)	$ (2,828,000)				$ (2,828,000)
Balance, shares at Mar. 31, 2018		49,999	533,781,064
Balance, amount at Mar. 31, 2018	$ 5,333,000		$ 534,000	$ 67,289,000	$ (62,490,000)
Net Income (Loss)	$ (2,213,000)				$ (2,213,000)
Balance, shares at Jun. 30, 2018		49,999	533,781,064
Balance, amount at Jun. 30, 2018	$ 3,120,000		$ 534,000	$ 67,289,000	$ (64,703,000)
Net Income (Loss)	$ 324,000				$ 324,000
Balance, shares at Sep. 30, 2018		49,999	533,781,064
Balance, amount at Sep. 30, 2018	$ 3,444,000		$ 534,000	$ 67,289,000	$ (64,379,000)
Balance, shares at Dec. 31, 2018		49,999	533,781,064
Balance, amount at Dec. 31, 2018	$ (150,000)		$ 534,000	$ 67,289,000	$ (67,973,000)
Net Income (Loss)	$ (436,000)				$ (436,000)
Balance, shares at Mar. 31, 2019		49,999	533,781,064
Balance, amount at Mar. 31, 2019	$ (586,000)		$ 534,000	$ 67,289,000	$ (68,409,000)
Net Income (Loss)	(908,000)				$ (908,000)
Options issued for services	7,000			7,000
Common stock issued for services, shares			24,000,000
Common stock issued for services, amount	$ 360,000		$ 24,000	$ 336,000
Balance, shares at Jun. 30, 2019		49,999	557,781,064
Balance, amount at Jun. 30, 2019	$ (1,127,000)		$ 558,000	$ 67,632,000	$ (69,317,000)
Net Income (Loss)	$ 1,229,000				$ 1,229,000
Balance, shares at Sep. 30, 2019		49,999	557,781,064
Balance, amount at Sep. 30, 2019	$ 102,000		$ 558,000	$ 67,632,000	$ (68,088,000)

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686

+ Details

XML 21 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 22 R24.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS EQUITY (DEFICIT) (Detail Narrative) - USD ($)	3 Months Ended	6 Months Ended	9 Months Ended
	Jun. 30, 2019	Jun. 30, 2019	Sep. 30, 2019	Sep. 30, 2018
Option exercisable price		$ 0.015
Share issued Option Services		500,000
Share issued Option Services, amount		$ 7,000
Option expected life		5 years
Common stock issued for service, value			$ 360,000
Director [Member]
Common stock issued for services, shares	24,000,000
Common stock issued for service, value	$ 360,000
Market price per share	$ 0.015

XML 23 R20.htm IDEA: XBRL DOCUMENT

INVESTMENT IN IMAGION BIOSYSTEMS (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
sale of common stock shares			100,000
Proceeds from sale of common stock shares			$ 2,480
Investment	$ 2,117,000		2,117,000		$ 1,354,000
(Loss) on fair value adjustment of investments	$ (1,397,000)	$ (646,000)	$ (764,000)	$ 2,727,000
Imagion Biosystems, Inc., [Member]
Common stock acquired shares	63,999,476		63,999,476
Fair value of Shares			$ 2,114,000
Noncontrolling interest rate	31.00%		31.00%
Noncontrolling interest rate decreased	19.00%		19.00%
Trading price per share	$ 0.033		$ 0.033
Investment
(Loss) on fair value adjustment of investments			$ (764,000)

XML 24 R14.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES	9 Months Ended
COMMITMENTS AND CONTINGENCIES	Sep. 30, 2019
COMMITMENTS AND CONTINGENCIES
NOTE 8 - COMMITMENTS AND CONTINGENCIES	As of September 30, 2019, we did not have any known commitments or contingencies. Legal matter contingencies The Company believes, based on current knowledge and after consultation with counsel, that it is not currently party to any material pending proceedings, individually or in the aggregate, the resolution of which would have a material effect on the Company. Provisions for losses are established in accordance with ASC 450, “Contingencies” when warranted. Once established, such provisions are adjusted when there is more information available of when an event occurs requiring a change.

XML 25 R10.htm IDEA: XBRL DOCUMENT

INVESTMENT IN IMAGION BIOSYSTEMS	9 Months Ended
INVESTMENT IN IMAGION BIOSYSTEMS	Sep. 30, 2019
INVESTMENT IN IMAGION BIOSYSTEMS
NOTE 4 - INVESTMENT IN IMAGION BIOSYSTEMS	As of September 30, 2019, the Company owns 63,999,476 shares of Imagion Biosystems (Imagion), resulting in a noncontrolling interest of Imagions issued and outstanding common stock. Initially, the Company held approximately 31% of Imagions total issued and outstanding common stock and was later was decreased to approximately 19%. Based upon Imagions trading price on September 30, 2019, approximately $0.033 per share, the fair value of the Imagion shares was approximately $2,114,000. During the nine months ended September 30, 2019, the Company recorded an unrealized gain in its investment of $764,000. During the nine months ended September 30, 2019, the Company sold 100,000 shares of Imagion and received cash proceeds of $2,480.

XML 26 R3.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2019	Dec. 31, 2018
Preferred stock, shares par value	$ .001	$ .001
Preferred stock, shares authorized	447,804	447,804
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, shares authorized	950,000,000	950,000,000
Common stock, shares issued	557,781,064	533,781,064
Common stock, shares outstanding	557,781,064	533,781,064
Series D convertible preferred Stock [Member]
Preferred stock, shares authorized	105,671	105,671
Preferred stock, shares issued	105,671	105,671
Preferred stock, shares outstanding	105,671	105,671
Class A Convertible Preferred Stock [Member]
Preferred stock, shares authorized	182,525	182,525
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Class B Convertible Preferred Stock [Member]
Preferred stock, shares authorized	250,000	250,000
Preferred stock, shares issued	49,999	49,999
Preferred stock, shares outstanding	49,999	49,999
Class C Redeemable Convertible Preferred Stock [Member]
Preferred stock, shares authorized	14,000	14,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

XML 27 R18.htm IDEA: XBRL DOCUMENT

GOING CONCERN (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
GOING CONCERN (Details Narrative) - USD ($)	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
GOING CONCERN
Working capital deficit	$ (1,565,000)		$ (1,565,000)
Cumulative losses	(68,088,000)		(68,088,000)		$ (67,973,000)
Net income (loss)	$ 1,229,000	$ 324,000	$ (115,000)	$ (4,717,000)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 28 R7.htm IDEA: XBRL DOCUMENT

BASIS OF PRESENTATION	9 Months Ended
BASIS OF PRESENTATION	Sep. 30, 2019
BASIS OF PRESENTATION
NOTE 1 - BASIS OF PRESENTATION	The foregoing unaudited interim financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions for Form 10-Q and Regulation S-X as promulgated by the Securities and Exchange Commission (“SEC”). Accordingly, these financial statements do not include all of the disclosures required by generally accepted accounting principles in the United States of America for complete financial statements. These unaudited interim financial statements should be read in conjunction with the audited financial statements and the notes thereto included on Form 10-K for the year ended December 31, 2018, filed on March 29, 2019. In the opinion of management, the unaudited interim financial statements furnished herein include all adjustments, all of which are of a normal recurring nature, necessary for a fair statement of the results for the interim period presented. The preparation of financial statements in accordance with generally accepted accounting principles in the United States of America requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published, and the reported amounts of revenues and expenses during the reporting period. Uncertainties with respect to such estimates and assumption are inherent in the preparation of the Company’s financial statements; accordingly, it is possible that the actual results could differ from these estimates and assumptions that could have a material effect on the reported amounts of the Company’s financial position and results of operations. Operating results for the nine-month period ended September 30, 2019 are not necessarily indicative of the results that may be expected for the year ending December 31, 2019. The condensed consolidated balance sheet at December 31, 2018 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by generally accepted accounting principles in the U.S. for complete financial statements.

ZIP 29 0001477932-19-006712-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001477932-19-006712-xbrl.zip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�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end XML 30 R22.htm IDEA: XBRL DOCUMENT v3.19.3

LICENSE AGREEMENT (Details Narrative)
9 Months Ended

Sep. 30, 2019

USD ($)

LICENSE AGREEMENT (Details Narrative)

Minimum Royalty Payment $ 50,000

Royalty percentage on dental products 10.00%

Royalty percentage on other licensed products 5.00%

XML 31 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 32 R23.htm IDEA: XBRL DOCUMENT

REVENUE (Detail Narrative) - USD ($)	3 Months Ended		9 Months Ended
REVENUE (Detail Narrative) - USD ($)	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
REVENUE
Revenue	$ 22,000		$ 72,000

XML 33 R2.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Current assets:
Cash	$ 144,000	$ 87,000
Prepaid expenses	6,000	11,000
Due from the sale of assets - current portion	300,000
Total current assets	450,000	98,000
Investment in equity securities	2,117,000	1,354,000
Property and equipment, net	6,000	6,000
Assets held for sale		1,200,000
Due from the sale of assets held for sale	600,000
Other assets	2,000	2,000
Total assets	3,175,000	2,660,000
Current liabilities:
Accounts payable and accrued expenses	237,000	221,000
Accrued expenses - related parties	1,778,000	1,531,000
Total current liabilities	2,015,000	1,752,000
Long-term liabilities:
Total long-term liabilities
Total liabilities	2,015,000	1,752,000
Commitments and Contingencies - Note 8
STOCKHOLDERS' EQUITY (DEFICIT)
Capital stock $.001 par value Preferred, authorized 447,804 shares, 0 and 0 shares issued, and outstanding, respectively
Capital stock $.001 par value Common, authorized 950,000,000 shares, 557,781,064 and 533,781,064 shares issued, and outstanding, respectively	558,000	534,000
Additional paid-in-capital	67,632,000	67,289,000
Accumulated deficit	(68,088,000)	(67,973,000)
Total stockholders' equity (deficit)	102,000	(150,000)
TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' EQUITY (DEFICIT)	3,175,000	2,660,000
Series D convertible preferred Stock [Member]
STOCKHOLDERS' EQUITY (DEFICIT)
Series D convertible preferred mandatory redeemable, authorized 105,671 shares, 105,671 and 105,671 shares issued and outstanding, respectively	1,058,000	1,058,000
Class A Convertible Preferred Stock [Member]
STOCKHOLDERS' EQUITY (DEFICIT)
Capital stock $.001 par value Preferred, authorized 447,804 shares, 0 and 0 shares issued, and outstanding, respectively
Class B Convertible Preferred Stock [Member]
STOCKHOLDERS' EQUITY (DEFICIT)
Capital stock $.001 par value Preferred, authorized 447,804 shares, 0 and 0 shares issued, and outstanding, respectively
Class C Redeemable Convertible Preferred Stock [Member]
STOCKHOLDERS' EQUITY (DEFICIT)
Capital stock $.001 par value Preferred, authorized 447,804 shares, 0 and 0 shares issued, and outstanding, respectively

XML 34 R19.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details Narrative) - USD ($)	3 Months Ended			9 Months Ended		12 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2009	Dec. 31, 2008	Dec. 31, 2018
Cash FDIC insured amount	$ 250,000			$ 250,000
Diluted shares excluded				40,105,000	50,798,182
Amortization period of values acquisition		10 years
Asset Imapairment					$ 842,000
Proceed from sale of asset		$ 300,000		$ 1,200,000
Description assets held for sale				The remaining $900,000 will be collected during the next three years in equal increments on the anniversary date of the agreement.
Common stock, shares issued	557,781,064			557,781,064				533,781,064
License agreements[Member] \| Metallicum [Member]
Amortization period of values acquisition							10 years
Purchase price of licences under agreement							$ 305,000
Los Alamos National Security LLC [Member] \| Patent license agreement [Member]
Common stock, shares issued						2,000,000
Purchase price of licences under agreement						$ 33,000
Purchase price of licenses under agreement						Purchase price paid for this license agreement was $33,000 based on the fair market value of 2,000,000 shares of common stock issued
Annual license fee						$ 10,000

XML 35 R6.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (115,000)	$ (4,717,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Common stock issued for services	360,000
Stock options issued/vested for services	7,000
Depreciation and amortization	1,000	496,000
Asset impairment		842,000
Gain (loss) on fair value adjustment of investments	(764,000)	2,727,000
Changes in:
Prepaid expenses	5,000	7,000
Accounts payable and accrued expenses	263,000	118,000
Net cash used in operating activities	(243,000)	(527,000)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of fixed assets	(2,000)
Proceeds from sale of assets held for sale	300,000	500,000
Proceeds from sale of investments	2,000
Net cash used in investing activities	300,000	500,000
CASH FLOWS FROM FINANCING ACTIVITIES:
Net cash provided by financing activities
NET DECREASE IN CASH	57,000	(27,000)
CASH, BEGINNING OF PERIOD	87,000	269,000
CASH, END OF PERIOD	144,000	242,000
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Interest paid
Income taxes paid

XML 36 R15.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS EQUITY (DEFICIT)	9 Months Ended
STOCKHOLDERS EQUITY (DEFICIT)	Sep. 30, 2019
STOCKHOLDERS EQUITY (DEFICIT)
NOTE 9 - STOCKHOLDERS EQUITY (DEFICIT)	During the three months ended June 30, 2019, the Company issued 24,000,000 shares of common stock to its board of directors for services valued at $360,000. The shares were valued based on the market price of the Company’s common shares of $0.015 on the grant date. During the three months ended June 30, 2019, the Company issued 500,000 options to its advisors for services valued at approximately $7,000. The options are exercisable at $0.015 and have a life of 5 years.

XML 37 R11.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE	9 Months Ended
NOTES PAYABLE	Sep. 30, 2019
NOTES PAYABLE
NOTE 5 - NOTES PAYABLE	On March 11, 2019, the Company received a loan for $50,000 and entered into a promissory note and security agreement with a third party. The loan was secured with ECAP-C machines. The due date of the loan was the earlier of April 30, 2019 or the closing of the transaction with the third party. Interest shall accrue at a rate of 6% per annum from April 11, 2019 until paid in full. On May 1, 2019, the transaction closed and agreements were executed. The Company repaid the $50,000 upon closing of the transaction.

EXCEL 38 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 39 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3 html 95 197 1 false 15 0 false 4 false false R1.htm 0000001 - Document - Document and Entity Information Sheet http://mhtx.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://mhtx.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://mhtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) Sheet http://mhtx.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) Statements 4 false false R5.htm 0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (unaudited) Sheet http://mhtx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficitUnaudited CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (unaudited) Statements 5 false false R6.htm 0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) Sheet http://mhtx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) Statements 6 false false R7.htm 0000007 - Disclosure - BASIS OF PRESENTATION Sheet http://mhtx.com/role/BasisOfPresentation BASIS OF PRESENTATION Notes 7 false false R8.htm 0000008 - Disclosure - GOING CONCERN Sheet http://mhtx.com/role/GoingConcern GOING CONCERN Notes 8 false false R9.htm 0000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS Sheet http://mhtx.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMatters SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS Notes 9 false false R10.htm 000010 - Disclosure - INVESTMENT IN IMAGION BIOSYSTEMS Sheet http://mhtx.com/role/InvestmentInImagionBiosystems INVESTMENT IN IMAGION BIOSYSTEMS Notes 10 false false R11.htm 000011 - Disclosure - NOTES PAYABLE Notes http://mhtx.com/role/NotesPayable NOTES PAYABLE Notes 11 false false R12.htm 000012 - Disclosure - LICENSE AGREEMENT Sheet http://mhtx.com/role/LicenseAgreement LICENSE AGREEMENT Notes 12 false false R13.htm 000013 - Disclosure - REVENUE Sheet http://mhtx.com/role/REVENUE REVENUE Notes 13 false false R14.htm 000014 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://mhtx.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 14 false false R15.htm 000015 - Disclosure - STOCKHOLDERS EQUITY (DEFICIT) Sheet http://mhtx.com/role/StockholdersEquityDeficit STOCKHOLDERS EQUITY (DEFICIT) Notes 15 false false R16.htm 000016 - Disclosure - SUBSEQUENT EVENTS Sheet http://mhtx.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 16 false false R17.htm 000017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Policies) Sheet http://mhtx.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Policies) Policies 17 false false R18.htm 000018 - Disclosure - GOING CONCERN (Details Narrative) Sheet http://mhtx.com/role/GoingConcernDetailsNarrative GOING CONCERN (Details Narrative) Details http://mhtx.com/role/GoingConcern 18 false false R19.htm 000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details Narrative) Sheet http://mhtx.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details Narrative) Details http://mhtx.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersPolicies 19 false false R20.htm 000020 - Disclosure - INVESTMENT IN IMAGION BIOSYSTEMS (Details Narrative) Sheet http://mhtx.com/role/InvestmentInImagionBiosystemsDetailsNarrative INVESTMENT IN IMAGION BIOSYSTEMS (Details Narrative) Details http://mhtx.com/role/InvestmentInImagionBiosystems 20 false false R21.htm 000021 - Disclosure - NOTES PAYABLE (Details Narrative) Notes http://mhtx.com/role/NotesPayableDetailsNarrative NOTES PAYABLE (Details Narrative) Details http://mhtx.com/role/NotesPayable 21 false false R22.htm 000022 - Disclosure - LICENSE AGREEMENT (Details Narrative) Sheet http://mhtx.com/role/LicenseAgreementDetailsNarrative LICENSE AGREEMENT (Details Narrative) Details http://mhtx.com/role/LicenseAgreement 22 false false R23.htm 000023 - Disclosure - REVENUE (Detail Narrative) Sheet http://mhtx.com/role/RevenueDetailNarrative REVENUE (Detail Narrative) Details http://mhtx.com/role/REVENUE 23 false false R24.htm 000024 - Disclosure - STOCKHOLDERS EQUITY (DEFICIT) (Detail Narrative) Sheet http://mhtx.com/role/StockholdersEquityDeficitDetailNarrative STOCKHOLDERS EQUITY (DEFICIT) (Detail Narrative) Details http://mhtx.com/role/StockholdersEquityDeficit 24 false false All Reports Book All Reports mhtx-20190930.xml mhtx-20190930.xsd mhtx-20190930_cal.xml mhtx-20190930_def.xml mhtx-20190930_lab.xml mhtx-20190930_pre.xml http://fasb.org/us-gaap/2019-01-31 http://fasb.org/srt/2019-01-31 http://xbrl.sec.gov/dei/2018-01-31 true true

	September 30,			December 31,
	2019			2018
	(unaudited)
ASSETS
Current assets:
Cash	$	144,000		$	87,000
Prepaid expenses		6,000			11,000
Due from the sale of assets - current portion		300,000			-
Total current assets		450,000			98,000

Investment in equity securities		2,117,000			1,354,000
Property and equipment, net		6,000			6,000
Assets held for sale		-			1,200,000
Due from the sale of assets held for sale		600,000			-
Other assets		2,000			2,000
Total assets	$	3,175,000		$	2,660,000

LIABILITIES
Current liabilities:
Accounts payable and accrued expenses	$	237,000		$	221,000
Accrued expenses — related parties		1,778,000			1,531,000
Total current liabilities		2,015,000			1,752,000

Long-term liabilities:
Total long-term liabilities		-			-
Total liabilities		2,015,000			1,752,000

Commitments and Contingencies - Note 8

Series D convertible preferred mandatory redeemable, authorized 105,671 shares, 105,671 and 105,671 shares issued and outstanding, respectively		1,058,000			1,058,000

STOCKHOLDERS’ EQUITY (DEFICIT)
Capital stock $.001 par value
Preferred, authorized 447,804 shares, 0 and 0 shares issued, and outstanding, respectively		-			-
Class A Convertible Preferred, authorized 182,525, 0 and 0 shares issued and outstanding, respectively		-			-
Class B Convertible Preferred, authorized 250,000, 49,999 and 49,999 shares issued and outstanding, respectively		-			-
Class C Redeemable Convertible Preferred, authorized 14,000, 0 and 0 shares issued and outstanding, respectively		-			-
Common, authorized 950,000,000 shares, 557,781,064 and 533,781,064 shares issued, and outstanding, respectively		558,000			534,000
Additional paid-in-capital		67,632,000			67,289,000
Accumulated deficit		(68,088,000	)		(67,973,000	)
Total stockholders' equity (deficit)		102,000			(150,000	)
TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS’ EQUITY (DEFICIT)	$	3,175,000		$	2,660,000

LICENSE AGREEMENT (Details Narrative)	9 Months Ended
LICENSE AGREEMENT (Details Narrative)	Sep. 30, 2019 USD ($)
LICENSE AGREEMENT (Details Narrative)
Minimum Royalty Payment	$ 50,000
Royalty percentage on dental products	10.00%
Royalty percentage on other licensed products	5.00%